# Community venomics reveals intra-species variations in venom composition of a local population of *Vipera kaznakovi* in Northeastern Turkey

4

Daniel Petras<sup>a,b,\*,^</sup>, Benjamin-Florian Hempel<sup>a,\*</sup>, Bayram Göçmen<sup>c</sup>, Mert Karis<sup>c</sup>, Gareth Whiteley<sup>d</sup>,
Simon C. Wagstaff<sup>e</sup>, Paul Heiss<sup>a</sup>, Nicholas R. Casewell<sup>d</sup>, Ayse Nalbantsoy<sup>f,^</sup> and Roderich D.
Süssmuth<sup>a,^</sup>

8

9 <sup>a</sup> Technische Universität Berlin, Institut für Chemie, Strasse des 17. Juni 124, 10623 Berlin, Germany.

<sup>b</sup> University of California San Diego, Collaborative Mass Spectrometry Innovation Center, 9500 Gilman Drive, La Jolla,
 California 92093, United States.

12 <sup>c</sup> Zoology Section, Department of Biology, Faculty of Science, Ege University, 35100 Bornova, Izmir, Turkey.

<sup>d</sup> Centre for Snakebite Research & Interventions, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3
 5QA, United Kingdom

15 <sup>e</sup> Bioinformatics Unit, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, United Kingdom

<sup>f</sup> Department of Bioengineering, Faculty of Engineering, Ege University, Bornova, 35100 Izmir, Turkey.

17 \* These authors contributed equally to this study

18 ^ Correspondence to dpetras@ucsd.edu, analbantsoy@gmail.com or roderich.suessmuth@tu-berlin.de

19 20

### 21 Abstract

22 We report on the variable venom composition of a population of the Caucasus viper (Vipera 23 kaznakovi) in Northeastern Turkey. We applied a combination of venom gland transcriptomics, 24 as well as de-complexing bottom-up and top-down venomics, enabling the comparison of the 25 venom proteomes from multiple individuals. In total, we identified peptides and proteins from 26 15 toxin families, including snake venom metalloproteinases (svMP; 37.8%), phospholipases A<sub>2</sub> 27 (PLA<sub>2</sub>; 19.0%), snake venom serine proteinases (svSP; 11.5%), C-type lectins (CTL; 6.9%) and 28 cysteine-rich secretory proteins (CRISP; 5.0%), in addition to several low abundant toxin 29 families. Furthermore, we identified intra-species variations of the V. kaznakovi venom 30 composition, and find these were mainly driven by the age of the animals, with lower svSP 31 abundance in juveniles. On a proteoform level, several small molecular weight toxins between 5 32 and 8 kDa in size, as well as PLA<sub>2</sub>s, drove the difference between juvenile and adult individuals. 33 This study provides first insights into venom variability of V. kaznakovi and highlights the utility 34 of intact mass profiling for a fast and detailed comparison of snake venoms of individuals from 35 a community.

36

37

# 38 Biological Significance

39 Population level and ontogenetic venom variation (e.g. diet, habitat, sex or age) can cause a loss of 40 antivenom efficacy against snake bites from wide ranging snake populations. The state of the art for 41 the analysis of snake venoms are de-complexing bottom-up proteomics approaches. While useful, 42 these have the significant drawback of being time-consuming and following costly protocols, and 43 consequently are often applied to pooled venom samples. To overcome these shortcomings and to 44 enable rapid and detailed profiling of large numbers of individual venom samples, we integrated an 45 intact protein analysis workflow into a transcriptomics-guided bottom-up approach. The application 46 of this workflow to snake individuals of a local population of V. kaznakovi revealed intra-species 47 variations in venom composition, which are primarily explained by the age of the animals, and 48 highlighted svSP abundance to be one of the molecular drivers for the compositional differences. 49

#### 50 Highlights

- First community venomic analysis of a local population of the Caucasian viper (*Vipera kaznakovi*).
- The venom gland transcriptome of *V. kaznakovi* identified 46 toxin genes relating to 15 venom
   toxin families.
- Bottom-up venomics revealed the identification of 25 proteins covering 7 toxin families mainly
   dominated by snake venom metalloproteinases (svMP).
- Community venomics by top-down mass profiling revealed ontogenetic shifts between juvenile
  and adult snakes.
- 59
- Keywords: Viperidae, Snake, Middle East, Toxin, Caucasian viper, *Vipera kaznakovi*, Snake
  Venomics, Transcriptomics, Top-down Venomics, Community Venomics, Venom
- 62

# 63

#### 64 **1. Introduction**

65 Venomics is considered an integrative approach, combining proteomics, transcriptomics and 66 genomics to study venoms [1]. Although the term was initially used to describe the mass 67 spectrometry-based proteomic characterization of venoms [2,3], genomic [4,5] or more commonly 68 venom gland transcriptomic sequencing [6-14] have also been used to characterize venom 69 compositions. These molecular approaches render an overview over venom composition by providing 70 the nucleotide sequences of venom toxin-encoding genes (among others) and, in the case of 71 transcriptomics, provide an estimation of their relative expression in the venom gland. Furthermore, 72 (translated) protein sequence databases are crucial for the robust annotation of tandem mass spectra 73 from proteomic analyses in peptide/protein spectrum matching (PrSM). A bibliographic search to the 74 keyword "Snake venomics" in PubMed identified 147 hits between 2004 and 2018, which showed 75 particularly in recent years a rapid expansion in the application of venomics approaches.

76 Initial proteomic analyses of snake venoms included the combination of multidimensional separation 77 techniques (chromatographic and gel electrophoresis), N-terminal Edman degradation, and *de novo* 78 sequencing by tandem mass spectrometry of tryptic peptides gathered by in-gel digestion of SDS-79 PAGE bands [2,15]. Since these initial studies, the proteomic characterization of snake venoms has 80 become much more comprehensive due to technical advances in mass spectrometry and next 81 generation nucleotide sequencing. Several complementary strategies were developed to unveil the 82 venom proteomes of more than 100 snake species [16]. Most of these studies applied the so called 83 'bottom-up' proteomics whereby intact proteins are typically digested with trypsin before tandem 84 mass spectrometry analysis. Many workflows perform venom decomplexation prior to the digestion 85 either by liquid chromatography (LC) or gel electrophoresis, or a combination of both [17]. The 86 direct, in-solution digestion, or so called 'shotgun proteomics', allows for a fast qualitative overview, 87 but suffers from a less quantitative breakdown of snake venom composition [17,18]. For example, in 88 shotgun experiments, the problem of protein inference often does not permit the differentiation of the 89 numerous toxin isoforms present in venom [19]. Thus, the chromatographic or electrophoretic 90 separation of venom samples greatly aids in differentiating between toxin isoforms (paralogs). In 91 addition, decomplexing prior to trypsin digestion often does not allow for a clear identification of 92 differential post-translational modified variants, so-called proteoforms [20].

93 A logical bypass of this problematic would be the omittance of the digestion step and the direct 94 analysis of intact proteins by tandem mass spectrometry, called top-down proteomics. Recently top-95 down protein analysis has been applied alone or in combination with other venomics approaches to 96 study the venom of King Cobra (Ophiophagus hannah) [21,22] the entire genus of mambas 97 (Dendroaspis spp.) [23,24], the brown tree snake (Boiga irregularis) [6], the Okinawa Habu Pit Viper 98 (Protobothrops flavoviridis) [25] and several viper species from Turkey [26–28]. In the case of 99 viperid species, top-down analysis typically only reveals a partial characterization of the venom, as a 100 number of the main toxin components, such as high molecular weight snake venom 101 metalloproteinases (svMPs) (>30 kDa), are challenging to efficiently ionize by denaturing 102 electrospray ionization (ESI) and might only provide few observable fragments in tandem MS [29]. A 103 possible way to overcome difficulties in terms of ionization of high molecular weight proteins is the 104 application of native ESI, as described by Melani et al. [22]. However native top-down mass 105 spectrometry typically requires a special type of mass spectrometer with extended mass range and 106 more extensive sample preparation, which makes this type of analysis more technically challenging.

In most of the aforementioned studies, the top-down workflow was performed with a front-end LCbased sample decomplexation. This allows for the generation of MS1 mass profiles (XICs) of intact
proteoforms. Typically, the MS1 information is accompanied by tandem MS (MS2) information

110 acquired in data-dependent acquisition (DDA) mode. The MS2 fragment spectra are than matched to a 111 translated transcriptome/genome database in order to identify the proteins. In the case that there are 112 not enough MS2 fragment peaks of a particular proteoform, the intact molecular mass can still enable 113 identification, especially if the intact mass can be associated to masses observed in complementary 114 experiments, such as retention time, mass range of SDS-PAGE and/or bottom-up protein IDs of 115 decomplexed bottom-up venomics [26]. The additional information gained through exact intact 116 protein masses can be particularly informative to differentiate between isoforms or proteoforms. 117 Furthermore, the simple sample preparation, high sensitivity and fast analysis time allows for a rapid 118 comparison of the venom composition. The quantitative capabilities of top-down approaches [30–32] 119 thereby offer great potential for comparative venomic studies of individuals. While most snake venom 120 compositions reported so far [16] were performed on a single pool of venom sourced from different 121 numbers of individuals, several studies have shown correlations between different ecological, 122 geographical, genetic and/or developmental factors and the venom proteome, e.g. different diets [33– 123 36], regional separation of populations [37–39], sex [40–42] or age [43–46]. In addition to better 124 understand the heritability of venom toxins [47], and the evolutionary processes underpinning 125 population level venom variations [48], venomics is an important approach to better understand 126 regional and intraspecific variations in the venom composition of medically important snake species, 127 which has considerable relevance for the development and clinical utility of snakebite therapies, 128 known as antivenom [49,50].

129 Here, we applied a top-down venomics approach to demonstrate intraspecific venom variation in a 130 local population of the medical relevant Caucasian viper (Vipera kaznakovi). The Caucasian viper is a 131 subtropical, medium-sized, viper species with a distribution range mainly at the Caucasian Black Sea 132 coast in the Artvin and Rize province of Turkey. V. kaznakovi feed predominately on small 133 vertebrates (mice, lizards etc.) and also insects [51]. In a previous shotgun proteomics study of this 134 species, Utkin and coworkers described the venom of V. kaznakovi to be composed of phospholipase 135 A<sub>2</sub> (PLA<sub>2</sub>), svMP, snake venom serine proteases (svSP), Cysteine-rich secretory proteins (CRISP), C-136 type lectins (CTL), L-amino acid oxidase (LAAO), vascular endothelial growth factor (VEGF), 137 disintegrins (Dis), phospholipase B (PLB), nerve growth factors (NGF), as well as other a number of

other proteins of lower abundance [52]. In this study, we pursue a more in-depth approach to characterizing the venom of this species. We use a combination of venom gland transcriptomics, decomplexing bottom-up proteomics and comparative top-down proteomics to broadly characterize the venom composition of this species, and to also investigate intraspecific variation in toxins on the level of the individual snakes.

143

#### 144 2. Material & Methods

145 2.1. Sampling

146 Venom samples of V. kaznakovi were collected from 6 adult (2 female, 4 male) and 3 juvenile 147 specimens (unknown sex). All specimens were captured in late June 2015 in their natural habitat and 148 released back into their natural environment after venom extraction. The V. kaznakovi individuals 149 were collected in Artvin province in Turkey near the Georgian border, with 6 individuals sampled 150 from Hopa district, 2 individuals from Borçka district and 1 specimen in the Arhavi district. An 151 additional female individual found in Borçka district was collected for venom gland dissection for 152 transcriptomics analysis. Ethical permission (Ege University Animal Experiments Ethics Committee, 153 2013#049) and special permission (2015#124662) for the sampling of wild-caught V. kaznakovi were 154 received from the Republic of Turkey, Ministry of Forestry and Water Affairs.

155

156 2.2. Sample storage and preparation

157 Crude *V. kaznakovi* venom was extracted by using a parafilm-covered laboratory beaker without 158 exerting pressure on the venom glands. Venom samples were centrifuged at  $2000 \times g$  for 10 min at 159 4 °C to remove cell debris. Supernatants were immediately frozen at -80 °C, lyophilized and samples 160 were stored at 4 °C until use.

161

162 2.3. Determination of lethal dose (LD<sub>50</sub>)

163 Lethal potency  $(LD_{50})$  of venoms to mice (milligrams of dry weight per kg) was determined by an up-164 and down method as recommended by the Organization for Economic Cooperation and Development 165 (OECD) guidelines (Test No. 425) [53,54]. Groups of five mice (n = 15; age, 8 to 10 weeks; female 8 166 and male 7 individuals) were used per venom dose. Various venom concentrations (5, 2 and 1 mg/kg, 167 milligrams of protein per kg calculated from dry weight venom by Bradford assay) were diluted in 168 ultrapure water to a final volume of 100 uL and injected by intraperitoneal (IP) routes. Control mice 169 (n = 5; female 2 and male 3 individuals) received a single IP injection of sterile saline (0.9%, 0.1 mL). 170 All assays and procedures involving animals strictly followed the ethical principles in animal research 171 adopted by the Swiss Academy of Medical Sciences [55]. Additionally, they were approved by a local 172 ethics committee (2013#049). The mortality was recorded 24 h after injection. The median lethal dose 173 was determined by a nonlinear regression fitting procedure (GraphPad Prism 5., Version 5.01, Inc., 174 San Diego, CA, USA).

175

176 2.4. RNA isolation and purification

Venom glands were dissected from a wild caught adult female specimen of *V. kaznakovi* in Kanlıdere, Hopa district (Artvin province) and processed as previously described [9,24]. Briefly, immediately following euthanasia, venom glands were dissected and were immediately flash frozen in liquid nitrogen and stored cryogenically prior to RNA extraction. Venom glands were next homogenized under liquid nitrogen and total RNA extracted using a TRIzol Plus RNA purification kit (Invitrogen), DNAse treated with the PureLink DNase set (Invitrogen) and poly(A) selected using the Dynabeads mRNA DIRECT purification kit (Life Technologies), as previously detailed [9,24].

184

185 2.5. RNA sequencing, assembly and annotation

186 RNA-Seq was performed as previously described [9,24]. The RNA-Seq library was prepared from 187 50 ng of enriched RNA material using the ScriptSeq v2 RNA-Seq Library Preparation Kit (epicenter, 188 Madison, WI, USA), following 12 cycles of amplification. The resulting sequencing library was 189 purified using AMPure XP beads (Agencourt, Brea, CA, USA), quantified using the Qubit dsDNA 190 HS Assay Kit (Life Technologies), before the size distribution was assessed using a Bioanalyser 191 (Agilent). The library was then multiplexed and sequenced (alongside other sequencing libraries not 192 reported in this study) on a single lane of an Illumina MiSeq, housed at the Centre for Genomic Research, Liverpool, UK. The V. kaznakovi library amounted to 1/6<sup>th</sup> of the total sequencing lane. The 193

ensuing read data was quality processed by (i) removing the presence of any adapter sequences using
Cutadapt (<u>https://code.google.com/p/cutadapt/</u>) and (ii) trimming low quality bases using Sickle
(<u>https://github.com/najoshi/sickle</u>). Reads were trimmed if bases at the 3' end matched the adapter
sequence for 3 bp or more, and further trimmed with a minimum window quality score of 20. After
trimming, reads shorter than 10 bp were removed.

199 For sequence assembly we used VTBuilder, a *de novo* transcriptome assembly program previously 200 designed and validated for constructing snake venom gland transcriptomes [56]. Paired-end read data 201 was entered into VTBuilder and executed with the following parameters: min. input read length 202 150 bp; min. output transcript length 300 bp; min. isoform similarity 96%. Assembled contigs were 203 annotated with the BLAST2GO Pro v3 [57] using the blastx-fast algorithm with a significance 204 threshold of 1e<sup>-5</sup>, to provide BLAST annotations (max 20 hits) against NCBI's non redundant (NR) 205 protein database (41 volumes: Nov 2015) followed by mapping to gene ontology terms, and Interpro 206 domain annotation using default parameters. Following generic annotation, venom toxins were 207 initially identified based on their BLAST similarity to sequences previously identified in the literature 208 or in molecular databases as snake venom toxins, and then manually curated for validation.

209

210 2.6. Venom proteomics (bottom-up)

211 The crude venom (1 mg) was dissolved to a final concentration of 10 mg/ml in aqueous 3% (v/v) 212 acetonitrile (ACN) with 1% (v/v) formic acid (FA) and centrifuged at 16,000 g for 5 min to spin down 213 insoluble content. The supernatant was loaded onto a semi-preparative reversed-phase HPLC with a 214 Supelco Discovery BIO wide Pore C18-3 column (4.6 x 150 mm, 3 µm particle size) using an Agilent 215 1260 Low Pressure Gradient System (Agilent, Waldbronn, Germany). The column was operated with 216 a flow rate of 1 mL/min and performed with ultrapure water (solution A) and ACN (solution B), both 217 including 0.1% (v/v) FA. A standard separation gradient was used with solution A and solution B, 218 starting isocratically (5% B) for 5 min, followed by linear gradients of 5-40% B for 95 min and 40-219 70% for 20 min, then 70% B for 10 min, and finally re-equilibration at 5% B for 10 min. Peak 220 detection was performed at  $\lambda = 214$  nm using a diode array detector (DAD). After the 221 chromatographic separation of the crude venom, the collected and vacuum-dried peak fractions were

222 submitted to a SDS-PAGE gel (12% polyacrylamide). Subsequently, the coomassie-stained bands 223 were excised, and submitted to in-gel trypsin digestion, reduced with fresh dithiothreitol (100 mM 224 DTT in 100 mM ammonium hydrogencarbonate, pH 8.3, for 30 min at 56 °C) and alkylated with 225 iodoacetamide (55 mM IAC in 100 mM ammonium hydrogencarbonate, pH 8.3, for 30 min at 25 °C 226 in the dark). The resulting peptides were then extracted with 100  $\mu$ L aqueous 30% (v/v) ACN just as 227 5% (v/v) FA for 15 min at 37 °C. The supernatant was vacuum-dried (Thermo speedvac, Bremen, 228 Germany), redissolved in 20 µL aqueous 3% (v/v) ACN with 1% (v/v) FA and submitted to LC-229 MS/MS analysis.

The bottom-up analysis were performed with an Orbitrap XL mass spectrometer (Thermo, Bremen, Germany) via an Agilent 1260 HPLC system (Agilent Technologies, Waldbronn, Germany) using a reversed-phase Grace Vydac 218MSC18 (2.1 x 150 mm, 5  $\mu$ m particle size) column. The prechromatographic separation was performed with the following settings: After an isocratic equilibration (5% B) for 1 min, the peptides were eluted with a linear gradient of 5-40% B for 10 min, 40-99% B in 3 min, held at 99% B for 3 min and re-equilibrated in 5% B for 3 min.

236

237 2.7. Community venom profiling (top-down)

238 The top-down MS analysis was performed by dissolving the crude venoms in ultrapure water 239 containing formic acid (FA, 1%) to a final concentration of 10 mg/mL, and centrifuged at 20,000 x g 240 for 5 min. Aliquots of 10 µL dissolved venom samples were submitted to reverse-phase (RP) HPLC-241 high-resolution (HR)-MS analyses. RP-HPLC-HR-MS experiments were performed on an Agilent 242 1260 HPLC system (Agilent, Waldbronn, Germany) coupled to an Orbitrap LTQ XL mass spectrometer (Thermo, Bremen, Germany). RP-HPLC separation was performed on a Supelco 243 244 Discovery Biowide C18 column (300 Å pore size,  $2 \times 150$  mm column size, 3 µm particle size). The 245 flow rate was set to 0.3 mL/min and the column was eluted with a gradient of 0.1% FA in water 246 (solution A) and 0.1% FA in ACN (solution B): 5% B for 5 min, followed by 5-40% B for 95 min, 247 and 40-70% for 20 min. Finally, the gradient was held isocratic with 70% B for 10 min and re-248 equilibrated at 5% B for 10 min. ESI settings were: 11 L/min sheath gas; 35 L/min auxiliary gas; 249 spray voltage, 4.8 kV; capillary voltage, 63 V; tube lens voltage, 135 V; and capillary temperature,

250 330 °C. MS/MS spectra were obtained in data-dependent acquisition (DDA) mode. FTMS 251 measurements were performed with 1 µ scans and 1000 ms maximal fill time. AGC targets were set to 252  $10^6$  for full scans and to  $3 \times 10^5$  for MS/MS scans, and the survey scan as well as both data dependent 253 MS/MS scans were performed with a mass resolution (R) of 100,000 (at m/z 400). For MS/MS the 254 two most abundant ions of the survey scan with known charge were selected. Normalized CID energy 255 was set to 30% for the first, and 35% for the second, MS/MS event of each duty cycle. The default 256 charge state was set to z = 6, and the activation time to 30 ms. Additional HCD experiments were 257 performed with 35% normalized collision energy, 30 ms activation time and z = 5 default charge 258 state. The mass window for precursor ion selection was set to 2 or 6 m/z. A window of 3 m/z was set 259 for dynamic exclusion of up to 50 precursor ions with a repeat of 1 within 10 s for the next 20 s.

260

#### 261 2.8. Bioinformatic analysis

262 The LC-MS/MS data files (.raw) obtained from the in-gel digestion were converted to mascot generic 263 format (.mgf) files via **MSConvert** GUI of the ProteoWizard package 264 (http://proteowizard.sourceforge.net; version 3.0.10328) and annotated by DeNovo GUI [58] 265 (version 1.14.5) with a mass accuracy of 10 ppm for precursor mass and 0.2 m/z for fragment peaks. 266 A fixed modification carbamidomethyl cysteine (C +57.02 Da) was selected. Resulting sequence tags 267 were examined manually and searched against the non-redundant Viperidae protein database (taxid: 268 8689) using the basic local alignment search tool (BLAST) [59].

269 For peptide spectrum matching, the SearchGUI software tool was used with XTandem! As the search 270 engine [60]. The MS2 spectra were searched against the non-redundant Viperidae protein NCBI 271 (taxid: 8689, 3rd Nov 2017, 1727 sequences), our in-house Vipera kaznakovi toxin sequence database 272 (translated from our venom gland transcriptomic analyses; 46 toxin sequences) and a set of proteins 273 found as common contaminants (CRAP, 116 sequences), containing in total 1889 sequences. Mass 274 accuracy was set to 10 ppm for the precursor mass and 0.2 m/z for the MS2 level. Alkylation of Cys 275 was set as fixed modification and acetylation of the N-terminus, of Lys as well as oxidation of Met 276 were allowed as variable modifications. A false discovery rate (FDR) was estimated through a target-

decoy approach and a cut-off of 1% was applied. All PSMs were validated manually and at least 2PSMs were required for a protein ID to be considered.

For the top-down data analysis, the .raw data were converted to .mzXML files using MSconvert of the

280 ProteoWizard package (<u>http://proteowizard.sourceforge.net;</u> version 3.0.10328), and multiple charged

spectra were deconvoluted using the XTRACT algorithm of the Xcalibur Qual Browser version 2.2

282 (Thermo, Bremen, Germany). For isotopically unresolved spectra, charge distribution deconvolution

283 was performed using the software tool <u>magic tran</u>sformer (MagTran).

284

285 2.9. Multivariable statistics

Principal component analysis (PCoA), using the relative percentages of the major toxin families as
well as different proteoforms as a variable, was applied to explain determinants of compositional
variation among venoms. PCoA was performed in R (R Foundation for Statistical Computing, 2016)
with the extension Graphic Package rgl, available from https://www.R-Project.org.

290

291 2.10. Data sharing

Mass spectrometry proteomics data (.mgf, .raw and results files and search database) have been deposited to ProteomeXchange [61] with the ID PXD010857 via the MassIVE partner repository under project name "Venom proteomics of *Vipera kaznakovi*" and massive ID MSV000082845.

Raw sequencing reads and the assembled contigs generated for the venom gland transcriptome (.fastq
and .fasta, respectively) have been deposited in the NCBI sequence read archive (SRA) under
accession SRR8198764 and linked to the BioProject identifier PRJNA505487.

298

## 299 3. Results and Discussion

**300** 3.1. Field work and venom toxicity

301 The medium-sized Caucasian viper (*Vipera kaznakovi*) mainly inhabits the forested slopes of 302 mountain peaks with a distribution range from the Caucasian Black Sea coast provinces of 303 northeastern Turkey, through Georgia to Russia (**Figure 1**). *V. kaznakovi* feeds predominately on 304 small vertebrates (mice, lizards, etc.) or insects, and a specific characteristic of this species is the

305 complete black coloration with elements of orange to red zigzag-looking strip on the upper side of the306 body (Figure 1).

307 During our fieldwork in June 2015 we collected nine V. kaznakovi individuals (6 adults and 3 308 juveniles) in their natural habitat, whose venom was extracted by using a parafilm-covered laboratory 309 beaker before the snakes were released back into their natural environment. The different V. kaznakovi 310 individuals were found in Hopa (6 spec.), Borcka (2 spec.) and Arhavi (1 spec.) districts of the Artvin 311 province (Figure 1). The LD<sub>50</sub> mean values of venom pooled from all collected V. kaznakovi 312 individuals was assessed by the intraperitoneal (IP) route using a random sample survey of five swiss 313 mice for three venom dose (5, 2 and 1 mg/kg), which is summarized in supplemental table 1. The 314  $LD_{50}$  mean value obtained for the pooled V. kaznakovi venom was calculated as ~2.6 mg/kg and can 315 categorized to have slightly weaker toxicity in this model, compared to other related viper species 316 (0.9-1.99 mg/kg) [62-65].

317

**318** 3.2. Venom gland transcriptomics

The *V. kaznakovi* venom gland transcriptome resulted in 1,742 assembled contigs, of which 46 exhibited gene annotations relating to 15 venom toxin families previously described in the literature (Figure 2). The majority of these contigs (33) encode genes, expressing toxin isoforms relating to four multi-locus gene families, namely the svMPs, CTLs, svSPs and PLA<sub>2</sub>s (Figure 2). Moreover, these four toxin families also exhibited the highest expression levels of the toxin families identified; in combination accounting for >78% of all toxin expressions (Figure 2). These findings are consistent with many prior studies of viperid venom gland transcriptomes [10,12,49,66,67].

The svMPs were the most abundantly expressed of the toxin families, accounting for 33.4% of the total toxin expression, and were encoded by 17 contigs (**Figure 2**). However, these contig numbers are likely to be an overestimation of the total number of expressed svMP genes found in the *V*. *kaznakovi* venom gland, as six of these contigs were incomplete and non-overlapping in terms of their nucleotide sequence, and therefore likely reflect a degree of low transcriptome coverage and/or underassembly. Of those contigs that we were able to identify to svMP class level (e.g. P-I, P-II or P-III [68,69]), ten exhibited structural domains unique to P-III svMPs, one to P-II svMPs and one to a short coding disintegrin. Interestingly, the svMP contig that exhibited the highest expression level encoded
for the sole P-II svMP (5.1% of all venom toxins), whereas the short coding disintegrin, which
exhibited 98% identity to the platelet aggregation inhibitor lebein-1-alpha from *Macrovipera lebetina*[70], was more moderately expressed (2.1%). Interestingly, we found no evidence for the
representation of the P-I class of svMPs in the *V. kaznakovi* venom gland transcriptome.

338 The CTLs were the next most abundant toxin family, with six contigs representing 27.5% of all toxin 339 gene expression (Figure 2). Interestingly, one of these CTLs, which exhibits the closest similarity to 340 snaclec-7 from Vipera ammodities venom (GenBank: APB93444.1), was by far the most abundantly 341 expressed toxin identified in the venom gland transcriptome (15.4% of all toxins) (Figure 2). We 342 identified lower expression levels for the multi-locus svSP and PLA<sub>2</sub> toxin families, which accounted 343 for 9.2% and 8.1% of the toxins, expressed in the venom gland transcriptome respectively, and were 344 encoded by seven and three contigs (Figure 2). Of the remaining toxin families identified, only two 345 exhibited expression levels >3% of the total toxin expression; CRISPs were encoded by two contigs 346 amounting to 5.4% of total toxin expression, and LAAO by a single contig representing 4.23% 347 (Figure 2). The remaining nine, lowly expressed, toxin families identified in the venom gland 348 transcriptome are displayed in Figure 2, and combined amounted to 12.1% of total toxin expression.

349

350 3.3 Decomplexed proteomics of pooled venom

351 To broadly characterize the venom composition of V. kaznakovi, in an initial experiment, we 352 performed bottom-up analysis of pooled venom by reversed phase-HPLC separation (Figure 3A) and 353 direct online intact mass analysis by ESI-HR-MS (Figure 3B). The prominent bands of the subsequent 354 separation by SDS-PAGE (Figure 3C) were excised followed by trypsin in-gel digestion and LC-355 MS/MS analysis. During the first analysis we did not have a species-specific transcriptome database 356 available, hence the spectra were analyzed by de novo sequencing. The resulting sequence tags were 357 searched against the NCBI non-redundant viperid protein database using BLAST [59]. The 57 358 sequence tags resulted in the identification of 25 proteins covering 7 toxin families (Table 1), namely 359 svMP, PLA<sub>2</sub>, svSP, CTL, CRISP, VEGF and LAAO.

360 De novo sequencing of MS/MS spectra of native small peptides (peaks 1-9) resulted in four additional 361 sequence tags and the identification of a svMP inhibitor (svMP-i) and two bradykinin potentiating 362 peptides (BPP). When we obtained the assembled transcriptome data, we re-analyzed the MS/MS data 363 from the tryptic peptides by peptide spectrum matching (PSM) using the translated protein sequences 364 of the transcriptome as well as the NCBI viperidae protein database. PSM resulted in 114 peptide 365 matches in total, which doubled the number of annotated spectra in comparison to the *de novo* 366 annotation. The analysis revealed the same seven major toxin families as identified by the tryptic de 367 novo tags, but showed with 29 identified proteins (compared to 25 by the above approach) a slight 368 improvement. Not surprisingly, most of the peptide matches were from the transcriptome derived 369 sequences and only six protein IDs came from other viperid sequences from the NCBI database. 370 Relative quantification through integration of the UV-HPLC peaks and densitometric analysis of the 371 SDS-gels revealed that the most abundant toxin families were svMP (37.7%), followed by PLA<sub>2</sub> 372 (19.0%), svSP (9.6%), LAAO (7.1%), CTL (6.9%), CRISP (5.0%), and VEGF (0.3%). In the small 373 molecular mass range < 2kDa, SVMP-i contributed 12.6%, BPP 2.0%, and unknown peptides 4.0% to 374 the overall venom composition (Figure 3D).

375 Comparing the abundance of venom toxins (Figure 3D) with transcriptomic predictions of expression 376 (Figure 2A), we observed an overall positive correlation, but we noted some major differences, 377 particularly relating to the CTLs: transcriptomic expression levels showed CTLs to be the second 378 most abundant toxin family (27.5% of all toxin contigs) while proteomic analysis shows a much lower 379 occurrence (6.9%). Interestingly, some of the molecular masses observed for CTLs (~20 kDa) during 380 SDS-PAGE did not correspond to the expected molecular mass derived from the transcriptome 381 sequence. As reported in other studies, we assume that some of the observed CTLs are hetero-dimers 382 [71]. SvMPs showed highly consistent profiles, as both the most abundantly expressed (33.4%) and 383 translated (32.7%) toxin family. Similarly, the svSPs (9.2%) and CRISPs (5.4%) exhibited 384 transcription levels highly comparable to their relative protein abundance in venom (9.6% and 385 5.02%). A lower transcription level was shown for  $PLA_2$  (8.1%) in contrast to the two times higher 386 protein level (19.0%). As anticipated, with the exception of VEGF (2.0% T; 0.4% P) and svMP-i

387 (1.7%; 12.6%) as part of the peptidic content, other lowly expressed 'toxin' families could not be388 assigned on the proteomic level.

389 The observed discrepancies in proteomic abundance and transcriptomic expression (e.g. CTLs and 390 PLA<sub>2</sub>s) is influenced by many factors, e.g. post-genomic factors acting on toxin genes [49], such as 391 the regulation of expression patterns by MicroRNAs (miRNA) [7,72], degradation processes [73], 392 systematic or stochastic variations [74] or technical limitations in the experimental approach, 393 including the eventually lower sensitivity of the proteomics workflow. Perhaps most importantly it 394 needs to be mentioned that here we compared the toxin transcription level of a single individual (adult female) to a pooled venom protein sample (n=9), and thus, while it is possible that these differences 395 396 are predominately due to the above mentioned regulatory processes, it seems likely that intra-specific 397 venom variations may influence our findings. Due to understandable sampling/ethical restrictions 398 relating to the sacrifice of individuals, we were unable to sequence venom gland transcriptomes of 399 multiple specimens of V. kaznakovi.

400 The previous proteomic characterization of the V. kaznakovi venom by Utkin and coworkers was 401 performed by in-solution trypsin proteolysis followed by nanoLC-MS/MS [52]. The PSM against a 402 full NCBI Serpentes database identified 116 proteins from 14 typical snake venom protein families. 403 The semi-quantitative venom composition showed PLA<sub>2</sub> (41%) as the most abundant component, 404 followed by svMPs (16%), CTL (12%), svSP (11%), CRISP (10%), LAAO (4%), VEGF (4%) and 405 other lowly abundant proteins (< 1%) [52]. Besides the additional detection of lowly abundant 406 proteins, the main difference to our results are the considerably higher levels of PLA<sub>2</sub> and the lower 407 abundance of svMPs (~ 4 fold difference for both protein families). The reasons for the additional 408 detection of lowly abundant proteins could be of technical nature, as the nanoLC-MS/MS and mass 409 spectrometer used in the study by Utkin et al., is typically more sensitive than the LC-MS/MS setup 410 we used. While explanations for the major differences in protein abundance could be the different 411 quantification method applied (UV abundance vs. summed peptide abundance [52]). Furthermore, the 412 observed variations could also be biological in nature, i.e. the result of intra-specific venom variation, 413 as the animals were collected in different geographic regions (Krasnodar Territory, Russia [51], with a 414 distance of  $\sim 400$  km to our collection site). However, as in most other venom proteomics studies the

415 composition was determined from a pooled venom sample (15 individuals [52]), which has the 416 potential to offset variation among individuals. In order to robustly assess the extent of intra-specific 417 (e.g. population level) variations in *V. kaznakovi* venom analysis of a representative group of 418 individuals is necessary.

419

420 3.4 Community venom profiling

421 It seems understandable that many venom studies are undertaken using pooled venom samples due to 422 the associated costs and analysis time of decomplexing bottom-up venomics studies. In our case, we 423 fractionated pooled venom from V. kaznakovi into 25 fractions and further separated the protein 424 containing fractions (MW > 5 kDa) by SDS-PAGE. This multidimensional separation resulted in 25 425 digested peptide samples which we analyzed by LC-MS/MS, requiring  $\sim 10 \text{ h}$  MS run time 426 (25 min/sample), and an estimated ~\$2,000 costs (\$80/sample). Multiplying this effort and cost by 427 numerous venom samples from individuals would of course make such a study comparatively 428 expensive. Hence, many previous studies investigating venom variability within a species have used 429 pooled venom for in-depth proteomic analysis, and then illuminated individual variability by the 430 comparison of HPLC chromatograms and/or SDS-PAGE images [50,75,76]. This comparison allows 431 at best a comparison at the protein family level (if protein families are clearly separated by HPLC or 432 SDS-PAGE). As an alternative, a comparison by top-down or shotgun proteomics would allow for the 433 differential comparison on the protein, or potentially proteoform, level performing a single LC-434 MS/MS run per individual.

However, shotgun approaches are likely to suffer from the aforementioned issues with protein inference, while top-down approaches have the drawback of not resolving high molecular mass proteins. This is particularly the case if the identification and comparison of proteins are based on Protein Spectrum Matching (PrSM), as high molecular weight toxins may not result in isotope resolved peaks and sufficient precursor signal, and thus are unlikely to provide sufficient fragment ions. However, a comparison by MS1 mass profiling only [77] would eliminate the problem of insufficient MS/MS fragments and isotope resolution, as spectra can be easily deconvoluted based on their charge state distribution. Such an approach could be particularly interesting for laboratories thatare equipped with low resolution mass spectrometers.

444 In order to explore the potential of venom comparison by top-down mass profiling, we analyzed the 445 venoms of nine V. kaznakovi individuals by LC-MS using the same chromatographic method as for 446 our initial HPLC separation of our decomplexing bottom-up venom analysis. Chromatographic peak 447 extraction of all individuals resulted in 119 consensus extracted ion chromatograms (XIC) or so-called 448 ion features. The alignment of XICs by retention time and mass enabled the comparison of samples 449 between individuals, but also a comparison with the mass profile of the pooled venom sample for a 450 protein level annotation. An overview of all resulting features, including annotations, is shown in 451 supplemental table 1. Looking at the binary distribution of ion features, individual venoms contained 452 between 62 and 107 features, with a slightly higher average feature number in juveniles vs. adults. 453 Comparing the total ion currents (TIC) of the LC-MS runs, the individual with the lowest feature 454 number also had the lowest overall signal. Hence it is likely that the lower number of features in this 455 individual was due to lower overall signal intensity and therefore might not be biologically 456 representative. For further statistical evaluation we thus normalized feature abundance to TIC. 457 Matching the features to the pooled bottom-up venomics results yielded an annotation rate between 458 83.4% and 93.5% of the features (based on XIC peak area). As anticipated, the annotation rate is 459 slightly lower than the relative annotation of the pooled sample (96.0%; based on the  $UV_{214}$  peak 460 area). The comparison of protein family venom compositions is shown in figure 4 and supplemental 461 table 2. The highest variance was observed for svSP, CTL and LAAO toxin families (Figure 5A). 462 Taking the age of the individuals into account, the abundance of svSPs was generally higher in the 463 adult individuals than in the juveniles (average of 21.7% vs. 5.5 %), but no significant difference 464 between male and female individuals, or between different geographic regions was observed. The 465 svSPs play a significant role in mammalian envenomation by affecting the hemostatic system through 466 perturbing blood coagulation, typically via the inducement of fibrinogenolytic effects [78,79]. Taking 467 this into account, a possible explanation could be that lower svSP concentration in juveniles could be 468 the result of differences in diet, as young animals typically prey on insects, before switching to feed 469 upon small mammals and lizards as they become adults [80–82]. Despite their observed variations in

470 abundance, no significant differences between the individual groups could be observed for the CTL 471 and LAAO toxin families (Figure 5A). However, there was evidence that the svSP concentration is 472 correlated to levels of LAAO, as the three individuals with the lowest svSP abundance showed the 473 highest content of LAAO (Figure 5A). Whether this is a true biological effect or perhaps is the result 474 of differences in ion suppression of the co-eluting compounds will need further investigation. We also 475 observed variations between the PLA<sub>2</sub> levels identified in the venoms, which ranged from 6.5-25.1%, 476 but in all cases remained lower than those previously reported by Kovalchuk et al. (41%) [52]. In 477 order to investigate the inner-species differences by multivariate statistics we performed a principal 478 coordinate analysis (PCoA) using the Bray-Curtis dissimilarity metric. The PCoA plots of protein-479 level and proteoform-level data is shown in figure 5. Clustering of individuals in protein-family level 480 PCoA space (Figure 5B) was only observed for the juvenile individuals. As expected from the 481 univariate statistics no significant separation based on gender or region could be observed. Since an 482 explanation for not resolving phenotype differences could be the reductions of variables through the 483 binning of proteoforms, we used proteoform abundance as input matrix for PCoA. The outcomes of 484 this analysis revealed a separation between both juvenile and adults, as well as between male and 485 female snakes (Figure 5C). To investigating the toxin variants underpinning these separations, we 486 used univariate comparison of the two groups and plotted the fold change of toxin abundance (log2) 487 vs. the statistical significance (-log10 p-value, t-test) shown in supplemental figure 2. Besides the 488 above mentioned differences in svSP, the most significant (p-value < 0.05, log2 fold change >2 or <-489 2) differences between juvenile and adult individuals was the higher abundance of small proteins with 490 the masses 7707.26 Da, 5565.02 Da, 5693.10 Da in the juvenile group, all of which were unidentified 491 in our proteomic analyses. Furthermore, we observed several smaller peptides with the masses 492 589.27 Da, 1244.56 Da, and 575.26 Da as well as a putative PLA<sub>2</sub>, with the mass of 13667.91 Da that 493 was more abundant in the juveniles. Contrastingly, a putative PLA<sub>2</sub> with a mass of 13683.86 Da was 494 of lower abundance in the juvenile group. While we observed fewer significant changes between the 495 venom toxins of the male and female individuals, the observed masses of the differential features 496 indicated, that those differential toxins belong to different protein families than those involved in 497 differentiating between juvenile and adult snakes. Two toxins with the masses 22829.66 Da and

498 24641.23 Da were higher abundant in male individuals and could be putatively annotated as hetero499 dimeric CTLs. Another toxin with the mass 13549.87 was also higher abundant in the male group and
500 according to the mass range is most likely a PLA<sub>2</sub>.

501

#### 502 4. Concluding remarks

503 Here we describe the detailed analysis of the venom composition of Vipera kaznakovi by a 504 combination of venom gland transcriptomics and decomplexing bottom-up and top-down venom 505 proteomics revealing the presence of 15 toxin families, of which the most abundant toxins were 506 svMPs (37.7%), followed by PLA<sub>2</sub>s (19.0%), svSPs (9.5%), CTLs (6.9%) and CRISP (5.0%). Intact 507 mass profiling enabled the rapid comparison of venom sourced from multiple individuals. This 508 community venomics approach enabled higher sensitivity of direct intact protein analysis by LC-MS, 509 in comparison to decomplexing bottom-up venomics, and thus enabled us working with multiple 510 venom samples and with low amounts of material (< 0.5 mg venom). This allowed us to capture the 511 snakes, perform venom extractions and then immediately release the animals back in to the field. Our 512 approach revealed intraspecific venom variation in Vipera kaznakovi, including both ontogenetic 513 differences between juvenile and adult snakes, and to a lesser extent, sexual differences between adult 514 males and females. The highest significant difference in venom proteome composition was found 515 between the adult and juvenile group, with svSP toxins found to exhibit the greatest variance. 516 However, in addition, individuals within all groups showed a generally high relative variance of CTL 517 and LAAO concentrations. svMPs on the other hand seemed to be constantly the most abundant 518 venom component in all V. kaznakovi individuals analyzed in our study. However, as the statistical 519 power with a relatively small subject size (n=9) is limited, it would be interesting to extend this study 520 to a larger sample cohort, ideally covering all geographical regions (from Northeastern Turkey to 521 Georgia and Russia) of the V. kaznakovi distribution zone. The workflow applied herein would be 522 well suited for an extensive venom analysis at the population level, and will hopefully enable venom 523 researchers to more easily expand their experimental approach towards robust comparisons of intra-524 species venom variation, and not only characterize pooled venom samples.

#### 525 Author contributions

- 526 D.P., A.N. and R.D.S. planned the study. D.P., A.N., B.G., M.K. and P.H. collected the animals and
- 527 prepared venom and venom gland tissue samples. A.N. performed the determination of acute lethal
- 528 dose. D.P., P.H. and B.-F.H. performed the toxin separation and acquired the mass spectrometry data.
- 529 G.W., S.C.W. and N.R.C. constructed the transcriptome. D.P., B.-F.H. and N.R.C. performed the data
- 530 analysis. A.N., N.R.C. and R.D.S. acquired funding and provided materials and instruments for the
- study. D.P., B.-F.H. and R.D.S. wrote the manuscript. All authors read, discussed and approved themanuscript.
- 533

# 534 Acknowledgements

535 We thank Sabah Ul-Hasan and Anthony Saviola for critical reading of the paper draft, and Robert

536 Harrison for assistance with transcriptomics. This study was supported by the Deutsche

537 Forschungsgemeinschaft (DFG) through the Cluster of Excellence 'Unifying Concepts in Catalysis

- 538 (UniCat), a postdoctoral research scholarship to D.P. (PE 2600/1), the Scientific and Technical
- 539 Research Council of Turkey (TÜBİTAK) under Grant 114Z946, and a Sir Henry Dale Fellowship
- 540 (200517/Z/16/Z) jointly funded by the Wellcome Trust and the Royal Society to N.R.C

# 541 References

- 542 [1] Calvete JJ, Lomonte B. A bright future for integrative venomics. Toxicon 2015;107(Pt B):159–
  543 62.
- 544 [2] Juárez P, Sanz L, Calvete JJ. Snake venomics: Characterization of protein families in Sistrurus
  545 barbouri venom by cysteine mapping, N-terminal sequencing, and tandem mass spectrometry
  546 analysis. Proteomics 2004;4(2):327–38.
- 547 [3] Calvete JJ. Snake venomics from low-resolution toxin-pattern recognition to toxin-resolved
  548 venom proteomes with absolute quantification. Expert Rev Proteomics 2018;15(7):555–68.
- 549 [4] Vonk FJ, Casewell NR, Henkel CV, Heimberg AM, Jansen HJ, McCleary RJR et al. The king
  550 cobra genome reveals dynamic gene evolution and adaptation in the snake venom system. Proc
  551 Natl Acad Sci U S A 2013;110(51):20651–6.
- [5] Aird SD, Arora J, Barua A, Qiu L, Terada K, Mikheyev AS. Population Genomic Analysis of a
   Pitviper Reveals Microevolutionary Forces Underlying Venom Chemistry. Genome Biol Evol
   2017;9(10):2640–9.
- [6] Pla D, Petras D, Saviola AJ, Modahl CM, Sanz L, Pérez A et al. Transcriptomics-guided bottomup and top-down venomics of neonate and adult specimens of the arboreal rear-fanged Brown
  Treesnake, Boiga irregularis, from Guam. J Proteomics 2018;174:71–84.

- 558 [7] Durban J, Sanz L, Trevisan-Silva D, Neri-Castro E, Alagón A, Calvete JJ. Integrated Venomics
  559 and Venom Gland Transcriptome Analysis of Juvenile and Adult Mexican Rattlesnakes Crotalus
  560 simus, C. tzabcan, and C. culminatus Revealed miRNA-modulated Ontogenetic Shifts. J
  561 Proteome Res 2017;16(9):3370–90.
- 562 [8] Aird SD, da Silva NJ, Qiu L, Villar-Briones A, Saddi VA, Pires de Campos Telles M et al.
  563 Coralsnake Venomics: Analyses of Venom Gland Transcriptomes and Proteomes of Six
  564 Brazilian Taxa. Toxins (Basel) 2017;9(6).
- [9] Pla D, Sanz L, Whiteley G, Wagstaff SC, Harrison RA, Casewell NR et al. What killed Karl
  Patterson Schmidt? Combined venom gland transcriptomic, venomic and antivenomic analysis
  of the South African green tree snake (the boomslang), Dispholidus typus. Biochim Biophys
  Acta 2017;1861(4):814–23.
- [10] Gonçalves-Machado L, Pla D, Sanz L, Jorge RJB, Leitão-De-Araújo M, Alves MLM et al.
  Combined venomics, venom gland transcriptomics, bioactivities, and antivenomics of two
  Bothrops jararaca populations from geographic isolated regions within the Brazilian Atlantic
  rainforest. J Proteomics 2016;135:73–89.
- 573 [11] Fry BG, Scheib H, L M Junqueira Azevedo I de, Silva DA, Casewell NR. Novel transcripts in
  574 the maxillary venom glands of advanced snakes. Toxicon 2012;59(7-8):696–708.
- 575 [12] Casewell NR, Harrison RA, Wüster W, Wagstaff SC. Comparative venom gland transcriptome
  576 surveys of the saw-scaled vipers (Viperidae: Echis) reveal substantial intra-family gene diversity
  577 and novel venom transcripts. BMC Genomics 2009;10:564.
- 578 [13] Rokyta DR, Wray KP, Margres MJ. The genesis of an exceptionally lethal venom in the timber
  579 rattlesnake (Crotalus horridus) revealed through comparative venom-gland transcriptomics.
  580 BMC Genomics 2013;14:394.
- [14] Tan CH, Tan KY, Fung SY, Tan NH. Venom-gland transcriptome and venom proteome of the
   Malaysian king cobra (Ophiophagus hannah). BMC Genomics 2015;16:687.
- [15] Nawarak J, Sinchaikul S, Wu C-Y, Liau M-Y, Phutrakul S, Chen S-T. Proteomics of snake
  venoms from Elapidae and Viperidae families by multidimensional chromatographic methods.
  Electrophoresis 2003;24(16):2838–54.
- 586 [16] Tasoulis T, Isbister GK. A Review and Database of Snake Venom Proteomes. Toxins (Basel)
   587 2017;9(9).
- 588 [17] Lomonte B, Calvete JJ. Strategies in 'snake venomics' aiming at an integrative view of
  589 compositional, functional, and immunological characteristics of venoms. J Venom Anim Toxins
  590 Incl Trop Dis 2017;23:26.
- [18] Melani RD, Goto-Silva L, Nogueira FCS, Junqueira M, Domont GB. Shotgun Approaches for
   Venom Analysis. In: Gopalakrishnakone P, Calvete JJ, editors. Venom Genomics and
   Proteomics: Venom Genomics and Proteomics. Dordrecht: Springer Netherlands; 2014, p. 1–12.
- [19] Nesvizhskii AI, Aebersold R. Interpretation of shotgun proteomic data: The protein inference
   problem. Mol Cell Proteomics 2005;4(10):1419–40.
- 596 [20] Smith LM, Kelleher NL. Proteoform: A single term describing protein complexity. Nat Methods
   597 2013;10(3):186–7.
- 598 [21] Petras D, Heiss P, Süssmuth RD, Calvete JJ. Venom Proteomics of Indonesian King Cobra,
  599 Ophiophagus hannah: Integrating Top-Down and Bottom-Up Approaches. J Proteome Res
  600 2015;14(6):2539–56.
- [22] Melani RD, Skinner OS, Fornelli L, Domont GB, Compton PD, Kelleher NL. Mapping
   Proteoforms and Protein Complexes From King Cobra Venom Using Both Denaturing and
   Native Top-down Proteomics. Mol Cell Proteomics 2016;15(7):2423–34.

- [23] Petras D, Heiss P, Harrison RA, Süssmuth RD, Calvete JJ. Top-down venomics of the East
  African green mamba, Dendroaspis angusticeps, and the black mamba, Dendroaspis polylepis,
  highlight the complexity of their toxin arsenals. J Proteomics 2016;146:148–64.
- 607 [24] Ainsworth S, Petras D, Engmark M, Süssmuth RD, Whiteley G, Albulescu L-O et al. The
  608 medical threat of mamba envenoming in sub-Saharan Africa revealed by genus-wide analysis of
  609 venom composition, toxicity and antivenomics profiling of available antivenoms. J Proteomics
  610 2018;172:173–89.
- 611 [25] Damm M, Hempel B-F, Nalbantsoy A, Süssmuth RD. Comprehensive Snake Venomics of the
  612 Okinawa Habu Pit Viper, Protobothrops flavoviridis, by Complementary Mass Spectrometry613 Guided Approaches. Molecules 2018;23(8).
- 614 [26] Göçmen B, Heiss P, Petras D, Nalbantsoy A, Süssmuth RD. Mass spectrometry guided venom
  615 profiling and bioactivity screening of the Anatolian Meadow Viper, Vipera anatolica. Toxicon
  616 2015;107(Pt B):163–74.
- 617 [27] Hempel B-F, Damm M, Göçmen B, Karis M, Oguz MA, Nalbantsoy A et al. Comparative
  618 Venomics of the Vipera ammodytes transcaucasiana and Vipera ammodytes montandoni from
  619 Turkey Provides Insights into Kinship. Toxins (Basel) 2018;10(1).
- [28] Nalbantsoy A, Hempel B-F, Petras D, Heiss P, Göçmen B, Iğci N et al. Combined venom profiling and cytotoxicity screening of the Radde's mountain viper (Montivipera raddei) and Mount Bulgar Viper (Montivipera bulgardaghica) with potent cytotoxicity against human A549 lung carcinoma cells. Toxicon 2017;135:71–83.
- 624 [29] Ghezellou P, Garikapati V, Kazemi SM, Strupat K, Ghassempour A, Spengler B. A perspective
   625 view of top-down proteomics in snake venom research. Rapid Commun Mass Spectrom 2018.
- [30] Wu S, Brown JN, Tolić N, Meng D, Liu X, Zhang H et al. Quantitative analysis of human salivary gland-derived intact proteome using top-down mass spectrometry. Proteomics 2014;14(10):1211–22.
- [31] Moehring F, Waas M, Keppel TR, Rathore D, Cowie AM, Stucky CL et al. Quantitative TopDown Mass Spectrometry Identifies Proteoforms Differentially Released during Mechanical
  Stimulation of Mouse Skin. J Proteome Res 2018;17(8):2635–48.
- [32] Ntai I, Toby TK, LeDuc RD, Kelleher NL. A Method for Label-Free, Differential Top-Down
  Proteomics. Methods Mol Biol 2016;1410:121–33.
- [33] Daltry JC, Wüster W, Thorpe RS. Diet and snake venom evolution. Nature 1996;379(6565):537–
  40.
- 636 [34] Barlow A, Pook CE, Harrison RA, Wüster W. Coevolution of diet and prey-specific venom
  637 activity supports the role of selection in snake venom evolution. Proc Biol Sci
  638 2009;276(1666):2443–9.
- 639 [35] Gibbs HL, Mackessy SP. Functional basis of a molecular adaptation: Prey-specific toxic effects
   640 of venom from Sistrurus rattlesnakes. Toxicon 2009;53(6):672–9.
- 641 [36] Gibbs HL, Sanz L, Sovic MG, Calvete JJ. Phylogeny-based comparative analysis of venom
  642 proteome variation in a clade of rattlesnakes (Sistrurus sp.). PLoS ONE 2013;8(6):e67220.
- [37] Alape-Girón A, Sanz L, Escolano J, Flores-Díaz M, Madrigal M, Sasa M et al. Snake venomics
  of the lancehead pitviper Bothrops asper: Geographic, individual, and ontogenetic variations. J
  Proteome Res 2008;7(8):3556–71.
- [38] Huang H-W, Liu B-S, Chien K-Y, Chiang L-C, Huang S-Y, Sung W-C et al. Cobra venom
  proteome and glycome determined from individual snakes of Naja atra reveal medically
  important dynamic range and systematic geographic variation. J Proteomics 2015;128:92–104.
- [39] Jorge RJB, Monteiro HSA, Gonçalves-Machado L, Guarnieri MC, Ximenes RM, Borges-Nojosa
   DM et al. Venomics and antivenomics of Bothrops erythromelas from five geographic

- populations within the Caatinga ecoregion of northeastern Brazil. J Proteomics 2015;114:93–
  114.
- [40] Pimenta DC, Prezoto BC, Konno K, Melo RL, Furtado MF, Camargo ACM et al. Mass
  spectrometric analysis of the individual variability of Bothrops jararaca venom peptide fraction.
  Evidence for sex-based variation among the bradykinin-potentiating peptides. Rapid Commun
  Mass Spectrom 2007;21(6):1034–42.
- [41] Menezes MC, Furtado MF, Travaglia-Cardoso SR, Camargo ACM, Serrano SMT. Sex-based
  individual variation of snake venom proteome among eighteen Bothrops jararaca siblings.
  Toxicon 2006;47(3):304–12.
- [42] Amorim FG, Costa TR, Baiwir D, Pauw E de, Quinton L, Sampaio SV. Proteopeptidomic,
  Functional and Immunoreactivity Characterization of Bothrops moojeni Snake Venom: Influence
  of Snake Gender on Venom Composition. Toxins (Basel) 2018;10(5).
- [43] Mackessy SP. Venom Ontogeny in the Pacific Rattlesnakes Crotalus viridis helleri and C. v.oreganus. Copeia 1988;1988(1):92.
- 665 [44] Gutiérrez JM, Avila C, Camacho Z, Lomonte B. Ontogenetic changes in the venom of the snake
   666 Lachesis muta stenophrys (bushmaster) from Costa Rica. Toxicon 1990;28(4):419–26.
- 667 [45] Guércio RAP, Shevchenko A, Shevchenko A, López-Lozano JL, Paba J, Sousa MV et al.
  668 Ontogenetic variations in the venom proteome of the Amazonian snake Bothrops atrox.
  669 Proteome Sci 2006;4:11.
- [46] Mackessy SP, Sixberry NM, Heyborne WH, Fritts T. Venom of the Brown Treesnake, Boiga irregularis: Ontogenetic shifts and taxa-specific toxicity. Toxicon 2006;47(5):537–48.
- [47] Calvete JJ, Casewell NR, Hernández-Guzmán U, Quesada-Bernat S, Sanz L, Rokyta DR et al.
  Venom Complexity in a Pitviper Produced by Facultative Parthenogenesis. Sci Rep 2018;8(1):11539.
- [48] Casewell NR, Wüster W, Vonk FJ, Harrison RA, Fry BG. Complex cocktails: The evolutionary
  novelty of venoms. Trends Ecol Evol (Amst ) 2013;28(4):219–29.
- [49] Casewell NR, Wagstaff SC, Wüster W, Cook DAN, Bolton FMS, King SI et al. Medically
  important differences in snake venom composition are dictated by distinct postgenomic
  mechanisms. Proc Natl Acad Sci U S A 2014;111(25):9205–10.
- [50] Massey DJ, Calvete JJ, Sánchez EE, Sanz L, Richards K, Curtis R et al. Venom variability and
  envenoming severity outcomes of the Crotalus scutulatus scutulatus (Mojave rattlesnake) from
  Southern Arizona. J Proteomics 2012;75(9):2576–87.
- [51] Starkov VG, Osipov AV, Utkin YN. Toxicity of venoms from vipers of Pelias group to crickets
   Gryllus assimilis and its relation to snake entomophagy. Toxicon 2007;49(7):995–1001.
- [52] Kovalchuk SI, Ziganshin RH, Starkov VG, Tsetlin VI, Utkin YN. Quantitative Proteomic
  Analysis of Venoms from Russian Vipers of Pelias Group: Phospholipases A<sub>2</sub> are the Main
  Venom Components. Toxins (Basel) 2016;8(4):105.
- 688 [53] Bruce RD. An up-and-down procedure for acute toxicity testing. Fundam Appl Toxicol
  689 1985;5(1):151–7.
- 690 [54] Cates CC, McCabe JG, Lawson GW, Couto MA. Core body temperature as adjunct to endpoint
  691 determination in murine median lethal dose testing of rattlesnake venom. Comp Med
  692 2014;64(6):440-7.
- Ethical principles and guidelines for experiments on animals. Swiss Academy of Medical
   Sciences. Swiss Academy of Sciences. Experientia 1996;52(1):1–3.
- 695 [56] Archer J, Whiteley G, Casewell NR, Harrison RA, Wagstaff SC. VTBuilder: A tool for the assembly of multi isoform transcriptomes. BMC Bioinformatics 2014;15:389.

- 697 [57] Götz S, García-Gómez JM, Terol J, Williams TD, Nagaraj SH, Nueda MJ et al. High-throughput
  698 functional annotation and data mining with the Blast2GO suite. Nucleic Acids Res
  699 2008;36(10):3420–35.
- [58] Muth T, Weilnböck L, Rapp E, Huber CG, Martens L, Vaudel M et al. DeNovoGUI: An open source graphical user interface for de novo sequencing of tandem mass spectra. J Proteome Res 2014;13(2):1143–6.
- [59] Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol
   Biol 1990;215(3):403–10.
- [60] Barsnes H, Vaudel M. SearchGUI: A Highly Adaptable Common Interface for Proteomics
  Search and de Novo Engines. J Proteome Res 2018;17(7):2552–5.
- [61] Vizcaíno JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Ríos D et al. ProteomeXchange
   provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol
   2014;32(3):223-6.
- [62] Sket D, Gubensek F, Adamic S, Lebez D. Action of a partially purified basic protein fraction
   from Vipera ammodytes venom. Toxicon 1973;11(1):47–53.
- [63] Oukkache N, El Jaoudi R, Ghalim N, Chgoury F, Bouhaouala B, Mdaghri NE et al. Evaluation
  of the lethal potency of scorpion and snake venoms and comparison between intraperitoneal and
  intravenous injection routes. Toxins (Basel) 2014;6(6):1873–81.
- [64] Calderón L, Lomonte B, Gutiérrez JM, Tarkowski A, Hanson LA. Biological and biochemical activities of Vipera berus (European viper) venom. Toxicon 1993;31(6):743–53.
- [65] Haro L de, Robbe-Vincent A, Saliou B, Valli M, Bon C, Choumet V. Unusual neurotoxic
  envenomations by Vipera aspis aspis snakes in France. Hum Exp Toxicol 2002;21(3):137–45.
- [66] Rokyta DR, Lemmon AR, Margres MJ, Aronow K. The venom-gland transcriptome of the eastern diamondback rattlesnake (Crotalus adamanteus). BMC Genomics 2012;13:312.
- [67] Junqueira-de-Azevedo ILM, Bastos CMV, Ho PL, Luna MS, Yamanouye N, Casewell NR.
   Venom-related transcripts from Bothrops jararaca tissues provide novel molecular insights into
   the production and evolution of snake venom. Mol Biol Evol 2015;32(3):754–66.
- Fox JW, Serrano SMT. Insights into and speculations about snake venom metalloproteinase
  (SVMP) synthesis, folding and disulfide bond formation and their contribution to venom
  complexity. FEBS J 2008;275(12):3016–30.
- [69] Casewell NR, Wagstaff SC, Harrison RA, Renjifo C, Wüster W. Domain loss facilitates
   accelerated evolution and neofunctionalization of duplicate snake venom metalloproteinase toxin
   genes. Mol Biol Evol 2011;28(9):2637–49.
- [70] Gasmi A, Srairi N, Guermazi S, Dekhil H, Dkhil H, Karoui H et al. Amino acid structure and
   characterization of a heterodimeric disintegrin from Vipera lebetina venom. Biochim Biophys
   Acta 2001;1547(1):51–6.
- [71] Navdaev A, Clemetson JM, Polgar J, Kehrel BE, Glauner M, Magnenat E et al. Aggretin, a
  heterodimeric C-type lectin from Calloselasma rhodostoma (Malayan pit viper), stimulates
  platelets by binding to α2β1 integrin and glycoprotein Ib, activating Syk and phospholipase Cγ 2,
  but does not involve the glycoprotein VI/Fc receptor γ chain collagen receptor. J Biol Chem
  2001;276(24):20882–9.
- [72] Durban J, Pérez A, Sanz L, Gómez A, Bonilla F, Rodríguez S et al. Integrated "omics" profiling
  indicates that miRNAs are modulators of the ontogenetic venom composition shift in the Central
  American rattlesnake, Crotalus simus simus. BMC Genomics 2013;14:234.
- [73] Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 2012;13(4):227–32.
- [74] Ruggles KV, Krug K, Wang X, Clauser KR, Wang J, Payne SH et al. Methods, Tools and
  Current Perspectives in Proteogenomics. Mol Cell Proteomics 2017;16(6):959–81.

- [75] Calvete JJ, Sanz L, Pérez A, Borges A, Vargas AM, Lomonte B et al. Snake population venomics and antivenomics of Bothrops atrox: Paedomorphism along its transamazonian dispersal and implications of geographic venom variability on snakebite management. J
  Proteomics 2011;74(4):510–27.
- [76] Galizio NdC, Serino-Silva C, Stuginski DR, Abreu PAE, Sant'Anna SS, Grego KF et al.
  Compositional and functional investigation of individual and pooled venoms from long-term captive and recently wild-caught Bothrops jararaca snakes. J Proteomics 2018;186:56–70.
- 752 [77] Fry BG, Wickramaratna JC, Hodgson WC, Alewood PF, Kini RM, Ho H et al. Electrospray
  753 liquid chromatography/mass spectrometry fingerprinting of Acanthophis (death adder) venoms:
  754 Taxonomic and toxinological implications. Rapid Commun Mass Spectrom 2002;16(6):600–8.
- [78] Serrano SMT. The long road of research on snake venom serine proteinases. Toxicon 2013;62:19–26.
- [79] Slagboom J, Kool J, Harrison RA, Casewell NR. Haemotoxic snake venoms: Their functional activity, impact on snakebite victims and pharmaceutical promise. Br J Haematol 2017;177(6):947–59.
- 760 [80] Dias GS, Kitano ES, Pagotto AH, Sant'anna SS, Rocha MMT, Zelanis A et al. Individual
  761 variability in the venom proteome of juvenile Bothrops jararaca specimens. J Proteome Res
  762 2013;12(10):4585–98.
- [81] Gibbs HL, Sanz L, Chiucchi JE, Farrell TM, Calvete JJ. Proteomic analysis of ontogenetic and diet-related changes in venom composition of juvenile and adult Dusky Pigmy rattlesnakes
  (Sistrurus miliarius barbouri). J Proteomics 2011;74(10):2169–79.
- [82] Zelanis A, Tashima AK, Rocha MMT, Furtado MF, Camargo ACM, Ho PL et al. Analysis of the ontogenetic variation in the venom proteome/peptidome of Bothrops jararaca reveals different strategies to deal with prey. J Proteome Res 2010;9(5):2278–91.
- [83] Geniez P. Snakes of Europe, North Africa & the Middle East: A photographic guide. Princeton:
   Princeton University Press; 2018.

771


**Table 1. Venom Protein Identifications from** *Vipera kaznakovi*. The table shows all protein identification of HPLC fractions (Fig. 3) by LC-MS and LC-MS/MS analysis from pooled venom. Peak numbering corresponds to the UV and MS chromatograms. Sequence tags were obtained by analysis of tryptic peptides by MS/MS de novo sequencing and/or peptide spectrum matching. Molecular weights of intact proteins were determined by SDS-PAGE and intact mass profiling (LC-MS).

| Pea<br>k  | Retetion<br>Time | SDS-PAGE<br>Band | Area% SDS-<br>PAGE | Area<br>(214<br>nm) | Mass<br>[Da]<br>(ESI-<br>MS) | Mass<br>[kDa]<br>(SDS-<br>PAGE) | Mass<br>tryptic<br>peptide<br>[m/z] | charge<br>[tryptic] | Sequence [PSM]                             | Prot-ID   | Mass tryptic peptide<br>[m/z] | char<br>ge | Seqence (de novo) | Identity (blast)  | e-<br>value       | Accession<br>Number      | Prote<br>in<br>Famil<br>y |  |
|-----------|------------------|------------------|--------------------|---------------------|------------------------------|---------------------------------|-------------------------------------|---------------------|--|---|-------------------------------|------------|-------------------|---|-------------------|--------------------------|---------------------------|--|
| 1         | 20.1             |                  |                    | 78423               | 443.22                       |                                 |                                     |                     |  |   | -                             | -          | pEQW              | tripeptide SVMPi  |                   | -                        | svMP-i                    |  |
| 2         | 27.4             |                  |                    | 3701                | 432.15                       |                                 |                                     |                     |  |   | -                             |            |                   | unknown   |                   | -                        | Peptide                   |  |
| 3         | 28.2             |                  |                    | 1928                | 3390.6                       |                                 |                                     |                     |  |   |                               |            |                   | unknown   |                   |                          | Peptide                   |  |
|           |                  |                  |                    | 11784               |                              |                                 |                                     |                     |  |   |                               |            |                   |   |                   |                          | replice                   |  |
| 4         | 30.3             |                  |                    |                     | 3942.84<br>860.3<br>822.40   |                                 |                                     |                     |  |   | -                             | -          | EPGEEDW           | unknown<br>Bradykinin-potentiating peptide<br>Bradykinin-potentiating peptide | -                 | BAN04688.1<br>BAN04688.1 | BPP<br>BPP                |  |
| 5         | 32.6             |                  |                    | 1075                | 3118.50                      |                                 |                                     |                     |  |   | -                             | -          |                   | unknown   | -                 | -                        | Peptide                   |  |
| 6         | 35.7             |                  |                    | 3117                | 680.29                       |                                 |                                     |                     |  |   | -                             | -          | -                 | unknown   | -                 | -                        | Peptide                   |  |
|           | 36.8             |                  |                    | 2039                | 3665.65                      |                                 |                                     |                     |  |   | -                             | -          | -                 | unknown   | -                 | -                        | Peptide                   |  |
| 7         |                  |                  |                    |                     | 13848.70                     |                                 |                                     |                     |  |   | -                             | -          | -                 | unknown   | -                 | -                        | unkno<br>wn               |  |
| 8         | 41.2             |                  |                    | 18410               | 1101.56                      |                                 |                                     |                     |  |   | -                             | -          | K/QPGPVSV         | unkown  |                   | -                        | Peptide                   |  |
|           | 49.7             |                  |                    | 2706                |                              |                                 |                                     |                     |  |   | -                             |            | -                 | unknown   |                   | -                        | unkow<br>n                |  |
| 9         |                  |                  |                    |                     | 7228.20                      |                                 |                                     |                     |  |   | -                             | -          | -                 | unknown   | -                 | -                        | unkow<br>n                |  |
|           | 50.4             |                  |                    | 6454                | 6680.95                      |                                 |                                     |                     |  |   |                               |            |                   |   |                   |                          |                           |  |
|           |                  | 10A              | 35%                |                     |                              | 14                              | 526.28                              | 2                   | PFXEVYQR                                   |   | 526.28                        | 2          | PFXEVYQR          | Nerve groth factor  | 2.2E-<br>02       | P83942.1                 |                           |  |
|           |                  |                  |                    |                     |                              |                                 | 556.8                               | 2                   | HTVDXQXM*R                                 | T0203_R_0.0314_L<br>_1049                         | 556.8                         | 2          | HTVDXQXMR         | Nerve groth factor  | 5.1E-<br>02       |                          | VEGF                      |  |
| 10        |                  |                  |                    |                     |                              |                                 | 1053.89                             | 3                   | ETXVPXXQEYPDEXSDXFRPSCVAV<br>XR            |   | -                             | -          | -                 | -   | -                 | -                        |                           |  |
| 10        |                  | 10B              | 65%                |                     |                              | 15                              | 903.93                              | 2                   | AAAXCFGENVNTYDKK                           | F8QN51.1  | 605.63                        | 3          | AAAXCAFGENVNTYDKK | acidic phospholipase A2   | 3.0E-<br>08       | F8QN51.1                 |                           |  |
|           |                  |                  |                    |                     |                              |                                 | 758.76                              | 2                   | pCCFVHDCCYGR                               |   | 853.46                        | 1          | NXFQFGK           | acidic phospholipase A2   | 1.1E+0<br>0       |                          | PLA2                      |  |
|           |                  |                  |                    |                     |                              |                                 | 910.38                              | 3                   | M*DTYSYSFXNGDXVCGDDPCXR                    | T1290_R_0.0575_L<br>_419                          | 616.77                        | 2          | MFCAGYXEGGK       | cationic trypsin-3-like   | 4.0E-<br>05       | XP_0156708<br>52.1       |                           |  |
|           | 61.21; 61.69     | 11,12            | 100%               | 456                 |                              |                                 | 796.67                              | 3                   | SAYGCYCGWGGQGRPQDPTDR                      |   | -                             | -          | -                 | -   | -                 | -                        |                           |  |
|           |                  | ,                |                    | 62431               | 13557.7;                     | 15                              | 900.93                              | 2                   | AAAXCFGENVN*TYDKK                          | F8QN51.1  | 605.63                        | 3          | AAAXCAFGENVNTYDKK | acidic phospholipase A2   | 3.0E-<br>08       | F8QN51.1                 |                           |  |
| 11,1<br>2 |                  |                  |                    |                     | 13540.8;<br>13523.7          |                                 | 1357.06                             | 2                   | M*DTYSYSFXN*GDXVCDGDDDPCX<br>R             |   | -                             |            | -                 | -   | -                 | -                        | PLA2                      |  |
|           |                  |                  |                    |                     |                              |                                 |                                     | 796.67              | 3  | SAYGCYCGWGGQGRPQDPTDR<br>SAXXSYSAYGCYCGWGGQGRPQDP | T1290_R_0.0575_L<br>_419      | -          | ·                 | -   | -                 |                          | -                         |  |
|           | 64.4             |                  |                    | 1798                |                              |                                 | 1008.12                             | 3                   | TDR  |   | -                             | -          | -                 | -   | •                 | -                        | unkno                     |  |
| 13        |                  |                  |                    |                     | 13541.78                     |                                 |                                     |                     |  |   |                               |            |                   |   |                   |                          | wn                        |  |
| 14        | 69.7             |                  |                    | 962                 | 24671.29                     |                                 |                                     |                     |  |   |                               |            |                   |   |                   |                          | unkno<br>wn               |  |
|           | 70.5             | 15A              | 71%                | 45974               | 24655.5                      | 25                              | 555.75                              | 2                   | Q*GCNNNYXK                                 |   | 545.94                        | 3          | QGCNNNYXK         | cyteine-rich venom protein  | 3.0E-             | B7FDI1.1                 |                           |  |
|           |                  |                  |                    |                     |                              |                                 | 692.38                              | 3                   | KPEXQN*EXXDXHNSXRR                         |   | 569.75                        | 2          | KPEXQNEXXDXHNSXR  | cyteine-rich venom protein  | 03<br>3.0E-       | XP_0156783               |                           |  |
|           |                  |                  |                    |                     |                              |                                 | 583.26                              | 2                   | NVDFDSESPR                                 |   | 640.34                        | 3          | WTAXXHEWHGEEK     | cyteine-rich venom protein  | 05<br>4.0E-<br>07 | 74.1<br>B7FDI1.1         |                           |  |
|           |                  |                  |                    |                     |                              |                                 | 769.34                              | 2                   | M*EWYPEAAANAER                             | B7FDI1.1  | 555.75                        | 2          | SVDFDSESPR        | cyteine-rich venom protein  | 2.0E-<br>05       | P86537.1                 | CRISP                     |  |
| 15        |                  |                  |                    |                     |                              |                                 | 581.3<br>526.24                     | 2<br>2              | SVNPTASNM*XK<br>VDFDSESPR                  |   | -                             |            | -                 | -   | -                 | -                        |                           |  |
|           |                  |                  |                    |                     |                              |                                 | 526.24<br>924.13                    | 3                   | VDFDSESPR<br>DFVYGQGASPANAVVGHYTQXVWY<br>K |   | -                             | -          | -                 | -   | -                 | -                        |                           |  |
|           |                  | 15B              | 29%                |                     | 13691.8                      | 13                              | 645.32                              | 2                   | HXSQFGDMXNK                                |   | 645.32                        | 2          | HXSQFGDMXNK       | ammodytin II(A) variant   | 6.0E-             | CAE47141.1               |                           |  |
|           |                  |                  |                    |                     |                              |                                 | 758.76                              | 2                   | pCCFVHDCCYGR                               | Q910A1  | -                             | -          | -                 | -   | - 04              | -                        | PLA2                      |  |
|           |                  |                  |                    |                     |                              |                                 | 620.96                              | 3                   | VAAXCFGENM*NTYDQKK                         |   | 625.63                        | 3          | VAAXCAFGENMNTYDQK | ammodytin II(A) variant   | 3.0E-<br>09       | CAE47176.1               |                           |  |

| Pea<br>k | Retetion<br>Time | SDS-PAGE<br>Band | Area% SDS-<br>PAGE | Area<br>(214<br>nm) | Mass<br>[Da]<br>(ESI-<br>MS) | Mass<br>[kDa]<br>(SDS-<br>PAGE) | Mass<br>tryptic<br>peptide<br>[m/z] | charge<br>[tryptic] | Sequence [PSM]                           | Prot-ID                   | Mass tryptic peptide<br>[m/z] | char<br>ge   | Seqence (de novo)             | Identity (blast)   | e-<br>value          | Accession<br>Number    | Prote<br>in<br>Famil<br>y |
|----------|------------------|------------------|--------------------|---------------------|------------------------------|---------------------------------|-------------------------------------|---------------------|--|---------------------------|-------------------------------|--------------|-------------------------------|--|----------------------|------------------------|---------------------------|
|          | 73.34; 74.43     | 27%              | 56120              | 51761               | 50                           | 655.69                          | 3                                   | FXTNFKPDCTXXRPSR    |  | 714.9                     | 2                             | VPXVGVEFWXNR | snake venom metalloproteinase | 5.0E-  | ADW54336.1           |                        |                           |
|          |                  | 17A              |                    |                     |                              | 50                              | 729.8                               | 2                   | SECDXPEYCTGK                             | T0053_R_0.0734_L          | 684.88                        | 2            | XVXVVDHSMVEK                  | III<br>snake venom metalloproteinase                           | 04<br>9.0E-          | ADI47673.1             | 10                        |
|          |                  |                  |                    |                     |                              |                                 | 594.28                              | 2                   | XGQDXYYCR                                | _1810                     | -                             | -            | AVAVVDRSMVEK                  | snake venom metanoprotemase                                    | 05                   | AD14/0/3.1             | svMP                      |
| 16,1     |                  |                  |                    |                     |                              |                                 | 570.95                              | 3                   | KEN*DVPXPCAPEDVK                         |                           | -                             | -            | -                             | -  | -                    | -                      |                           |
| 7        |                  | 16, 17B          | 73%                |                     | 13675.9                      | 14                              | 645.32                              | 2                   | HXSQFGDMXNK                              |                           | 645.32                        | 2            | HXSQFGDMXNK                   | ammodytin II(A) variant  | 6.0E-                | CAE47141.1             |                           |
|          |                  |                  |                    |                     |                              |                                 | 758.77                              | 2                   | pCCFVHDCCYGR                             |                           | -                             | -            | -                             | -  | 04                   | -                      |                           |
|          |                  |                  |                    |                     |                              |                                 | 620.96                              | 3                   | VAAXCFGEN*M*NTYDQKK                      | Q910A1                    | 625.63                        | 3            | VAAXCAFGENMNTYDQK             | ammodytin II(A) variant  | 3.0E-                | CAE47176.1             | PLA2                      |
|          |                  |                  |                    |                     |                              |                                 | 670.31                              | 2                   | YMLYSIFDCK                               |                           | -                             | -            |                               | -  | 09                   | -                      |                           |
|          | 80.6             |                  |                    | 90949               |                              |                                 |                                     |                     |  |                           |                               |              |                               |  | 1.05                 |                        |                           |
|          |                  | 18A              | 18%                |                     | N.D.                         | 65                              | 670.89                              | 2                   | XVXVVDHSM*VTK                            |                           | 670.89                        | 2            | XVXVVDHSMVTK                  | snake venom metalloproteinase<br>group III                     | 1.0E-<br>04<br>2.9E- | CAJ01689.1             |                           |
|          |                  |                  |                    |                     |                              |                                 | 540.79                              | 2                   | YN*SDXTVXR                               |                           | 540.79                        | 2            | YNSDXTVXR                     | snake venom metalloproteinase                                  | 01                   | ADI47687.1             |                           |
|          |                  |                  |                    |                     |                              |                                 | 710.39                              | 2                   | VPXVGVEXWDHR                             |                           | 710.39                        | 2            | VPXVGVEXWDHR                  | snake venom metalloproteinase                                  | 6.5E-<br>02          | ADI47590.1             |                           |
|          |                  |                  |                    |                     |                              |                                 | 571.79                              | 2                   | pQXVATSEQQR                              | T0033_R_0.0599_L          | -                             | -            |                               | -  | -                    | -                      | svMP                      |
|          |                  |                  |                    |                     |                              |                                 | 567.98<br>776.75                    | 3                   | VNXXNEM*YXPXNXR<br>KRHDNAQXXTTXDFDGSVXGK | _2024                     | -                             |              |                               |  | -                    | -                      | 571411                    |
|          |                  |                  |                    |                     |                              |                                 | 534.27                              | 3                   | HSVAXVEDYSPXDR                           |                           | -                             | -            |                               |  |                      | -                      |                           |
|          |                  |                  |                    |                     |                              |                                 | 645                                 | 3                   | FXTNDKPDCTXXRPSR                         |                           | -                             | -            | -                             | -  | -                    | -                      |                           |
|          |                  |                  |                    |                     |                              |                                 | 605.27                              | 2                   | KGESYFYCR                                |                           | 605.27                        | 2            | KGESYFYCR                     | snake venom metalloproteinase                                  | 9.0E-<br>05          | ADI47619.1             |                           |
|          |                  |                  |                    |                     |                              |                                 | 862.93                              | 2                   | KENDVPXPCAPEDXK                          |                           | -                             | -            |                               | -  | -                    | -                      |                           |
|          |                  | 18B              | 8%                 |                     | 51600                        | 50                              | 655.69                              | 3                   | FXTNFKPDCTXXRPSR                         | T0053_R_0.0734_L<br>_1810 | 714.9                         | 2            | VPXVGVEFWXNR                  | snake venom metalloproteinase<br>group III                     | 5.0E-<br>04          | ADW54336.1             |                           |
| 18       |                  |                  |                    |                     | 30133                        |                                 | 729.8                               | 2                   | SECDXPEYCTGK                             |                           | 684.88                        | 2            | XVXVVDHSMVEK                  | snake venom metalloproteinase                                  | 9.0E-<br>05          | ADI47673.1             | svMP                      |
|          |                  |                  |                    |                     |                              |                                 | 594.28<br>570.95                    | 2 3                 | XGQDXYYCR<br>KEN*DVPXPCAPEDVK            |                           | -                             | -            | -                             | -  | -                    | -                      |                           |
|          |                  | 18C              | 53%                |                     |                              | 35                              | 821.41                              | 3                   | VXGGDECNXNEHPFXVAXHTAR                   | T1255 P 0.005 I           | 835.4                         | 3            | VXGGDECANXNEHPFXAF            | snake venom serine proteinase                                  | 2.0E-                | E5AJX2.1               |                           |
|          |                  | 100              | 5576               |                     | 50155                        | 55                              |                                     |                     |  | T1355_R_0.005_L_<br>400   |                               |              | VTSDR                         | nikobin  | 12<br>3.0E-          |                        |                           |
|          |                  |                  |                    |                     |                              |                                 | 1057.03<br>587.81                   | 2                   | FYCAGTLXNQEWVXTAAR<br>VVCAGXWQGGK        |                           | 590.79<br>587.81              | 2            | XMGWGTXSSTK                   | snake venom serine proteinase<br>snake venom serine proteinase | 05<br>1.0E-          | ART88740.1<br>E5AJX2.1 |                           |
|          |                  |                  |                    |                     |                              |                                 |                                     |                     |  | E5AJX2                    |                               |              | -                             | nikobin  | 04<br>6.0E-          |                        | svSP                      |
|          |                  |                  |                    |                     |                              |                                 | 748.36                              | 3                   | C*AGTXXNQEWVXTAAHCNGK                    |                           | 612.82                        |              | snake venom serine proteinase | 04   | ADE45141.1           |                        |                           |
|          |                  |                  |                    |                     |                              |                                 | 611.01<br>890.51                    | 3<br>1              | XXPDVPHCANXEXXK<br>VHPEXPAK              |                           | -                             | -            | -                             | -  |                      | -                      |                           |
|          |                  | 18D              | 20%                |                     | 17249                        | 14                              | 633.63                              | 3                   | KTWEDAEKFCTEQAR                          |                           | 714.3                         | 2            | WTEDAENFCQK                   | C-type lectin snaclec-1  | 1.0E-<br>04          | AMB36338.1             |                           |
|          |                  |                  |                    |                     |                              |                                 | 597.79                              | 2                   | SPEEVDFM*XK                              | T0841_R_0.0782_L          | 597.79                        | 2            | SPEEVDFMXK                    | C-type lectin-like protein 2B                                  | 1.1E-                | AJO70722.1             | CTL                       |
|          |                  |                  |                    |                     |                              |                                 | 521.81                              | 2                   | ADXVWXGXR                                | _536                      | 584.33                        | 2            | HXATXEWXGK                    | C-type lectin snaclec A16                                      | 02<br>1.8E-<br>01    | B4XSZ1.1               |                           |
|          | 85.32; 86.63     |                  |                    | 32261               |                              |                                 |                                     |                     |  |                           |                               |              |                               |  | 01                   |                        |                           |
|          |                  | 19/20            | 100%               |                     | 49299                        | 50                              | 594.28                              | 2                   | XGQDXYYCR                                |                           | 594.28                        | 2            | XGQDXYYCR                     | zinc metalloproteinase<br>disintegrin-like                     | 1.4E-<br>01          | Q0NZX8.1               |                           |
|          |                  |                  |                    |                     |                              |                                 | 1053.5                              | 3                   | HDNAQXXTAXDFDGPTXGXAHMSS<br>MCQSK        |                           | 684.88                        | 2            | XVXVVDHSMVEK                  | snake venom metalloproteinase                                  | 9.0E-<br>05          | ADI47673.1             |                           |
| 19,2     |                  |                  |                    |                     |                              |                                 | 1111.51                             | 3                   | SVAFVEDYSPXDHMVASTMAHEMG<br>HNXGMR       | T0053_R_0.0734_L          | 714.9                         | 2            | VPXVGVEFWXNR                  | snake venom metalloproteinase<br>group III                     | 5.0E-<br>04          | ADW54336.1             |                           |
| 0        |                  |                  |                    |                     |                              |                                 | 655.68                              | 3                   | FXTNFKPDCTXXRPSR                         | _1810                     | 987.47                        | 2            | pEXVATSEQQSYYDRFR             | snake venom metalloproteinase                                  | 2.0E-<br>10          | ADI47633.1             | svMP                      |
|          |                  |                  |                    |                     |                              |                                 | 987.86                              | 2                   | SWVQCESGECCEQCR                          |                           | -                             |              |                               | -  | -                    |                        |                           |
|          |                  |                  |                    |                     |                              |                                 | 729.8                               | 2                   | SECDXPEYCTGK                             |                           | -                             | -            | -                             | -  | -                    | -                      |                           |
|          |                  |                  |                    |                     |                              |                                 | 570.95<br>1007.49                   | 3                   | KEN*DVPXPCAPEDVK<br>XYCEXVPN             |                           | -                             | -            | -                             | -  | -                    | -                      |                           |

| Pea<br>k | Retetion<br>Time | SDS-PAGE<br>Band | Area<br>%<br>SDS-<br>PAG<br>E | Area<br>(214<br>nm) | Mass [Da]<br>(ESI-MS) | Mass<br>[kDa]<br>(SDS-<br>PAGE) | Mass<br>tryptic<br>peptide<br>[m/z] | charge<br>[tryptic] | Sequence [PSM]                               | Prot-ID                   | Mass tryptic peptide<br>[m/z]              | charg<br>e | Seqence (de novo)        | Identity (blast)                            | e-<br>value                                 | Accessio<br>n<br>Number | Protei<br>n<br>Famil<br>y |      |
|----------|------------------|------------------|-------------------------------|---------------------|-----------------------|---------------------------------|-------------------------------------|---------------------|--|---------------------------|--|------------|--------------------------|---|---|-------------------------|---------------------------|------|
|          | 91.3             |                  |                               | 52573               |                       |                                 |                                     |                     |  |                           |  |            |                          |   |   | BAN82140                |                           |      |
|          |                  | 21               | 100%                          |                     | 57374                 | 60                              | 634.86                              | 2                   | VGEVNKDPGXXK                                 |                           | 634.86                                     | 2          | VGEVNKDPGXXK             | L-amino acid oxidase                        | 7.0E-04                                     | .1                      |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 502.27                              | 2                   | VTVXEASER                                    |                           | 502.28                                     | 2          | VTVXEASER                | L-amino acid oxidase                        | 5.0E-02                                     | Q6WP39.1                |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 701.68                              | 3                   | NVEEGWYANXGPM*RXPEK<br>HXVVVGAGM*SGXSAAYVXAG | T0018_R_0.0657_L_2<br>450 | -  | -          | -                        | -   | -   | •                       | LAAO                      |      |
|          |                  |                  |                               |                     |                       |                                 | 755.74                              | 3                   | AGHK   | 450                       | -  | -          | -                        |   | -   | -                       |                           |      |
| 21       |                  |                  |                               |                     |                       |                                 | 676.86                              | 2                   | SAGQXYEESXKK                                 |                           | -  |            | -                        | -   | -   | -                       |                           |      |
| 21       |                  |                  |                               |                     |                       |                                 | 637.8                               | 2                   | TFCYPSMXQK                                   |                           | -  | -          | -                        | -   | -   | -                       |                           |      |
|          |                  |                  |                               |                     | N.D.                  | 50                              | 540.79                              | 2                   | YNSDXTVXR                                    |                           | 540.79                                     | 2          | YNSDXTVXR                | snake venom metalloproteinase               | 2.9E-01                                     | ADI47687.<br>1          |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 670.88                              | 2                   | XVXVVDHSMVTK                                 | T0033_R_0.0599_L_2        |  |            |                          |   |   | -                       |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 710.39                              | 2                   | VPXVGVEXWDHR                                 | 024                       |  | -          | -                        | -   | -   | -                       | svMP                      |      |
|          |                  |                  |                               |                     |                       |                                 | 534.27                              | 3                   | HSVAXVEDYSPXDR                               |                           | -  |            | -                        | -   | -   | -                       |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 575.62                              | 3                   | KENDVPXPCAPEDXK                              |                           |  |            | -                        | -   | -   | -                       |                           |      |
|          | 95.5             | 22A              | 58%                           | 15611               | N.D.                  | 65                              | 694.89                              | 2                   | XVXVVDHSM*FTK                                |                           | 694.89                                     | 2          | XVXVVDHSMFTK             | zinc metalloproteinase disintegrin-<br>like | 7.0E-04                                     | Q9IAX6.1                |                           |      |
|          |                  | 22A 3879 N.D.    |                               | 799.42              | 2                     | XYEM*VNTXNVVFR                  |                                     | 799.43              | 2  | XYEMVNTXNVVFR             | snake venom metalloproteinase              | 1.0E-06    | AMB36352                 |   |   |                         |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 747 89                              | 2                   | VAYVYYEM®WTNR T0039 R 0.0184 L 1 747.89 2    | KXVYXEMWTNR               | group III<br>snake venom metalloproteinase | 4.0E-04    | .1<br>AMB36352           |   |   |                         |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 737.95                              | 3                   | XHSWVECESGECCDQCR                            | 944                       |  | -          |                          | group III                                   |   | .1                      |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 728.35                              | 3                   | AXFGANAAVGQDACFDWNKK                         |                           |  |            | -                        | -   |   | -                       | svMP                      |      |
|          |                  |                  |                               |                     |                       |                                 | 517.21                              | 2                   | GTDDFYCR                                     |                           | -  |            | -                        | -   | -   | -                       |                           |      |
|          |                  |                  |                               |                     | 8415.90002            |                                 | 690.84                              | 2                   | XFCEIVPNTCK                                  |                           | -  | -          | -                        | -   | -   | -                       |                           |      |
| 22       |                  |                  |                               |                     |                       |                                 | 742.62                              | 3                   | XHSWVECESGECCEQCR                            | T0033_R_0.0599_L_2<br>024 | -  | -          | -                        | -   | -   | -                       |                           |      |
|          |                  | 22B              | 26%                           |                     | 48846                 | 50                              | 540.79                              | 2                   | YNSDXTVXR                                    | T0033_R_0.0599_L_2        | 540.79                                     | 2          | YNSDXTVXR                | snake venom metalloproteinase               | 2.4E+0<br>0                                 | CAJ01688.<br>1          |                           |      |
|          |                  |                  |                               |                     |                       |                                 |                                     | 534.27              | 3  | HSVAXVEDYSPXDR            | 024  | 645.62     | 3                        | STHSPDDPDYGMVDXGTK                          | zinc metalloproteinase disintegrin-<br>like | 2.0E-11                 | P0DJE2.3                  | svMP |
|          |                  |                  |                               |                     |                       |                                 | 799.42                              | 2                   | XYEM*VNTXNVVFR                               | T0039_R_0.0184_L_1<br>944 | 567.31                                     | 3          | XXCVKPPTGNXXSCK          | snake venom metalloproteinase               | 3.2E-01                                     | AHB62069<br>.1          |                           |      |
|          |                  | 22C              | 16%                           |                     | 19174                 | 20                              | 854.93                              | 2                   | TSADYVWXGXWNQR                               | T0790_R_0.0456_L_5        | 854.93                                     | 2          | TSADYVWXGXWNQR           | C-type lectin-like protein 2B               | 4.0E-09                                     | AJO70726.               | CTL                       |      |
|          |                  |                  |                               |                     |                       |                                 | 578.29                              | 2                   | WTDGSSVXYK                                   | 50                        | 517.26                                     | 2          | TTDNQWXR                 | C-type lectin snaclec 7                     | 2.0E-02                                     | Q4PRC6.1                | CIL                       |      |
| 23       | 96.4             | 23               |                               | 53265               | 48161;<br>59182.8     | 65                              | -                                   | -                   | -  | -                         | 588.32                                     | 2          | VPXPCANQVXK              | snake venom metalloproteinase               | 7.3E+0                                      | ADI47650.               | svMP                      |      |
|          | 104.6            |                  |                               | 38719               |                       |                                 |                                     |                     |  |                           |  |            |                          |   |   |                         |                           |      |
|          |                  | 24A              | 80%                           |                     | 57509                 | 65                              | 710.39                              | 2                   | VPXVGVEXWDHR                                 |                           | 710.39                                     | 2          | VPXVGVEXWDHR             | snake venom metalloproteinase               | 6.5E-02                                     | ADI47590.<br>1          |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 571.79                              | 2                   | pQXVATSEQQR                                  | T0033_R_0.0599_L_2<br>024 | -  | -          |                          | -   | -   | -                       |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 540.79                              | 2 2                 | YNSDXTVXR<br>VNXXNEMY XPXNXR                 |                           | -  | -          | -                        | -   | -   | -                       |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 851.47                              |                     |  |                           |  | -          | -                        | -   | -   | ADI47642.               | svMP                      |      |
|          |                  |                  |                               |                     |                       |                                 | 706.32                              | 2                   | SDPDY AM*VDXGTK                              |                           | 706.33                                     | 2          | SDPDY AMVDXGTK.          | snake venom metalloproteinase               | 7.0E-05                                     | 1                       |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 591.8                               | 2                   | SVGXXQDYCK                                   | T0039_R_0.0184_L_1<br>944 | -  |            | -                        | -   | -   | -                       |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 816.67                              | 3                   | CFNYNXQGTENFHCGMENGR                         |                           | 816.67                                     | 3          | CFNYNXQGTENFHCGMEN<br>GR | snake venom metalloproteinase               | 5.0E-14                                     | AHB62069<br>.1          |                           |      |
|          |                  |                  |                               |                     |                       |                                 |                                     |                     |  |                           |  |            |                          |   |   |                         |                           |      |
| 24       |                  | 24B              | 6%                            |                     | 30133                 | 30                              | 671.84                              | 2                   | XPSSPPSVGSVCR                                | T0596_R_0.0034_L_6        | 671.84                                     | 2          | XPSSPPSVGSVCR            | snake venom serine proteinase<br>isoform 7  | 3.0E-06                                     | ABG26973                |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 798.7                               | 3                   | FYCAGYQNNDWDKDXMXXK                          | 47                        | 803.38                                     | 3          | EVCAACYONNDWDKDYM        | snake venom serine proteinase SP-<br>3      | 8.0E-06                                     | AMB36344<br>.1          | svSP                      |      |
|          |                  |                  |                               |                     |                       |                                 |                                     |                     |  |                           |  |            |                          |   |   | AJO70722.               |                           |      |
|          |                  | 24C              | 14%                           |                     | 17061                 | 15                              | 597.79                              | 2                   | SPEEVDFM*XK                                  |                           | 597.79                                     | 2          | SPEEVDFMXK               | C-type lectin-like protein 2B               | 1.1E-02                                     | 1                       |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 633.63                              | 3                   | KTWEDAEKFCTEQAR                              | T0841_R_0.0782_L_5<br>36  | 633.63                                     | 3          | KTWEDAEKFCTEQAR          | C-type lectin snaclec 7                     | 4.0E-11                                     | B4XT06.1                |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 824.5                               | 1                   | GGHXXSXK                                     | 50                        | 584.33                                     | 2          | HXATXEWXGK               | C-type lectin snaclec A16                   | 1.8E-01                                     | B4XSZ1.1                | CTL                       |      |
|          |                  |                  |                               |                     |                       |                                 | 521.81                              | 2                   | ADXVWXGXR                                    |                           | · ·  | -          |                          | -   | -   | -                       |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 698.3                               | 2                   | AWSDEPNCFAAK                                 | T0512_R_0.2394_L_6        | -  | -          | -                        | -   | -   |                         |                           |      |
|          |                  |                  |                               |                     |                       |                                 | 595.31                              | 2                   | TTDNQWXRR                                    | 99                        | -  |            | -                        | -   | -   | -                       |                           |      |

| Pea<br>k | Retetion<br>Time | SDS-PAGE<br>Band | Area% SDS-<br>PAGE | Area<br>(214<br>nm) | Mass<br>[Da]<br>(ESI-<br>MS) | Mass<br>[kDa]<br>(SDS-<br>PAGE) | Mass<br>tryptic<br>peptide<br>[m/z] | charge<br>[tryptic] | Sequence [PSM]                | Prot-ID                   | Mass tryptic peptide<br>[m/z] | charg<br>e | Seqence (de<br>novo) | Identity (blast)                           | e-<br>value  | Accessio<br>n<br>Number | Protei<br>n<br>Famil<br>y |   |            |                               |         |                |  |
|----------|------------------|------------------|--------------------|---------------------|------------------------------|---------------------------------|-------------------------------------|---------------------|-------------------------------|---------------------------|-------------------------------|------------|----------------------|--|--------------|-------------------------|---------------------------|---|------------|-------------------------------|---------|----------------|--|
|          | 108.7            |                  |                    | 69780               |                              |                                 |                                     |                     |                               |                           |                               |            |                      |  |              |                         |                           |   |            |                               |         |                |  |
|          |                  | 25A              | 57%                |                     | 57516                        | 60                              | 755.74                              | 3                   | HXVVVGAGM*SGXSAAYVXAG<br>AGHK |                           | -                             | -          | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 502.27                              | 2                   | VTVXEASER                     |                           | -                             | -          | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 818.38                              | 2                   | NVEEGWYANXGPMR                | T0018_R_0.0657_L_2        | -                             | -          | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 859.43                              | 3                   | KFGXQXNEFVQETDNGWYFXK         | 450                       | -                             | -          | -                    | -  | -            | -                       | LAAO                      |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 634.86                              | 2                   | VGEVNKDPGXXK                  |                           | -                             | -          | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 612.81                              | 2                   | SAGQXYEESXK                   |                           | -                             | -          | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 747.7                               | 3                   | XFFAGEYTANAHGWXDSTXK          |                           | -                             | -          | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 710.39                              | 2                   | VPXVGVEXWDHR                  |                           | 710.39                        | 2          | VPXVGVEXWDH<br>R     | snake venom metalloproteinase              | 6.5E-02      | ADI47590.<br>1          |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 571.79                              | 2                   | pQXVATSEQQR                   |                           | -                             | -          | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
| 25       |                  |                  |                    |                     |                              |                                 |                                     |                     |                               |                           |                               |            | 670.88               | 2  | XVXVVDHSMVTK |                         | 656.31                    | 2 | NPCQXYYTPR | snake venom metalloproteinase | 6.0E-05 | AGL45259<br>.1 |  |
|          |                  |                  |                    |                     |                              |                                 | 540.79                              | 2                   | YNSDXTVXR                     | T0033_R_0.0599_L_2<br>024 | 540.79                        | 2          | YNSDXTVXR            | snake venom metalloproteinase              | 2.9E-01      | ADI47687.<br>1          | svMP                      |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 851.47                              | 2                   | VNXXNEM*YXPXNXR               |                           | -                             |            | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 682.02                              | 3                   | HDNAQXXTTXDFDGSVXGK           |                           | -                             |            | -                    | -  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 |                                     | 534.27              | 3                             | HSVAXVEDYSPXDR            |                               | -          |                      | -  | -            | -                       | -                         |   |            |                               |         |                |  |
|          |                  |                  |                    |                     |                              |                                 | 575.62                              | 3                   | KENDVPXPCAPEDXK               |                           | -                             | -          | -                    |  | -            | -                       |                           |   |            |                               |         |                |  |
|          |                  | 25B              | 16%                |                     | 30131                        | 30                              | -                                   | -                   |                               | -                         | 671.84                        | 2          | XPSSPPSVGSVCR        | snake venom serine proteinase<br>isoform 7 | 3.0E-06      | ABG26973<br>.1          | svSP                      |   |            |                               |         |                |  |
|          |                  | 25C              | 27%                |                     | N.D.                         | 15                              | -                                   | -                   | -                             | -                         | -                             | -          | -                    | -  | -            | -                       | CTL                       |   |            |                               |         |                |  |



**Figure 1. Geographical distribution and sampling localities of** *Vipera kaznakovi.* The distribution area of the Caucasian Viper (*Vipera kaznakovi*, genus *Viperidae*) is highlighted on the map in the lower right corner and adapted from Geniez *et al.* [83]. The locations and sex/age of the collected individuals are marked on the map (orange – adult male, red – adult female, blue - juvenile).







Figure 2. The relative expression levels of toxin families identified in the *Vipera kaznakovi* venom gland transcriptome. A The left pie chart shows the relative expression levels of the major toxin families, each of which accounts for greater than 4% of all toxins encoded in the venom gland. The right pie chart shows the relative expression levels of the remaining toxin families, which in combination account for 12.11% of all toxins encoded in the venom gland ("others"). Percentage values on both charts reflect the expression level of each toxin family as a percentage of the total expression of all identified toxin families. B The relative expression levels of individual contigs encoded by the most abundantly expressed toxin families (CTL, svMP, svSP and PLA<sub>2</sub>). Key: svMP – snake venom metalloproteinase; CTL – C-type lectin; svSP – snake venom serine protease; PLA<sub>2</sub> – phospholipase A<sub>2</sub>; CRISP – cysteine-rich secretory protein; LAAO – L-amino acid oxidase; kunitz – kunitz-type inhibitors; VEGF – vascular endothelial growth factor; PLA2-i – PLA<sub>2</sub> inhibitors, SVMP-i – SVMP inhibitors PLB – phospholipase B; NGF – nerve growth factor; RLAP – renin-like aspartic proteases; 5' Nuc – 5' nucleotidase.




**Figure 3. Bottom-up snake venomics of** *Vipera kaznakovi*. A Venom separation of *V. kaznakovi* was performed by a Supelco Discovery BIO wide Pore C18-3 RP-HPLC column and UV absorbance measured at  $\lambda = 214$  nm. **B** Total ion current (TIC) profile of crude *V. kaznakovi* venom. The peak nomenclature is based on the chromatogram fractions. **C** The RP-HPLC fractions (indicated above the lane) of the *V. kaznakovi* venom was analysed by SDS-PAGE under reducing conditions (Coomassie staining). Alphabetically marked bands per line were excised for subsequent tryptic in-gel digestion. **D** The relative occurrence of different toxin families of *V. kaznakovi* is represented by the pie chart. Identification of snake venom metalloproteinase (svMP, red), phospholipases A<sub>2</sub> (PLA<sub>2</sub>, blue), snake venom serine proteinase (svSP, green), C-type lectin like proteins (CTL, purple), cysteine rich secretory proteins (CRISP, light blue), bradykinin-potentiating peptides (BPP, light brown), vascular endothelial growth factors (VEGF-F, red), unknown proteins (n/a, black) and peptides (grey). The *de novo* identified peptides are listed in supplemental table 1.



**Figure 4. Intact molecular mass profiles of venom from several individuals of** *V. kaznakovi*. The total ion counts (TIC) of native, crude venoms from several *V. kaznakovi* individuals were measured by HPLC-ESI-MS. The relative abundance was set to 100% for the highest peak. The peak nomenclature is based on the chromatogram fractions and is shown in figure 3A. The identified molecular masses of intact proteins and peptides are listed in supplemental table 2. The intact molecular mass profiling includes three juveniles of unknown sex (blue circle), and two female (red Venus symbol) and four male (orange Mars symbol) adult individuals.



**Figure 5. Principal Component Analysis (PCoA) and relative venom composition of individual** *V. kaznakovi.* **A** The proteome overview includes three juveniles of unknown sex (blue circle), and two female (red Venus symbol) and four male (orange Mars symbol) adult individuals. The compositional similarity of venom is displayed through Bray-Curtis-Faith distance in PCoA space. Toxin similarity is visualized at the protein family level (**B**) and proteoform level (**C**).



**Graphical Abstract**